-
1
-
-
77951076005
-
Jean-Martin Charcot. 1825 to 1893
-
Clanet, M. Jean-Martin Charcot. 1825 to 1893. Int. MS J. 2008, 15, 59-61.
-
(2008)
Int. MS J
, vol.15
, pp. 59-61
-
-
Clanet, M.1
-
2
-
-
33749681309
-
Sex ratio of multiple sclerosis in Canada: A longitudinal study
-
Orton, S.M.; Herrera, B.M.; Yee, I.M.; Valdar, W.; Ramagopalan, S.V.; Sadovnick, A.D.; Ebers, G.C. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol. 2006, 5, 932-936.
-
(2006)
Lancet Neurol
, vol.5
, pp. 932-936
-
-
Orton, S.M.1
Herrera, B.M.2
Yee, I.M.3
Valdar, W.4
Ramagopalan, S.V.5
Sadovnick, A.D.6
Ebers, G.C.7
-
3
-
-
0025767289
-
HLA class II-associated genetic susceptibility in multiple sclerosis: A critical evaluation
-
Olerup, O.; Hillert, J. HLA class II-associated genetic susceptibility in multiple sclerosis: A critical evaluation. Tissue Antigens 1991, 38, 1-15.
-
(1991)
Tissue Antigens
, vol.38
, pp. 1-15
-
-
Olerup, O.1
Hillert, J.2
-
4
-
-
34548299105
-
Risk alleles for multiple sclerosis identified by a genomewide study
-
Hafler, D.A.; Compston, A.; Sawcer, S.; Lander, E.S.; Daly, M.J.; de Jager, P.L.; de Bakker, P.I.; Gabriel, S.B.; Mirel, D.B.; Ivinson, A.J.; et al. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 2007, 357, 851-862.
-
(2007)
N. Engl. J. Med
, vol.357
, pp. 851-862
-
-
Hafler, D.A.1
Compston, A.2
Sawcer, S.3
Lander, E.S.4
Daly, M.J.5
de Jager, P.L.6
de Bakker, P.I.7
Gabriel, S.B.8
Mirel, D.B.9
Ivinson, A.J.10
-
5
-
-
42549108701
-
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations
-
Weber, F.; Fontaine, B.; Cournu-Rebeix, I.; Kroner, A.; Knop, M.; Lutz, S.; Muller-Sarnowski, F.; Uhr, M.; Bettecken, T.; Kohli, M.; et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun. 2008, 9, 259-263.
-
(2008)
Genes Immun
, vol.9
, pp. 259-263
-
-
Weber, F.1
Fontaine, B.2
Cournu-Rebeix, I.3
Kroner, A.4
Knop, M.5
Lutz, S.6
Muller-Sarnowski, F.7
Uhr, M.8
Bettecken, T.9
Kohli, M.10
-
6
-
-
34248647881
-
Active induction of experimental allergic encephalomyelitis
-
Stromnes, I.M.; Goverman, J.M. Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 2006, 1, 1810-1819.
-
(2006)
Nat. Protoc
, vol.1
, pp. 1810-1819
-
-
Stromnes, I.M.1
Goverman, J.M.2
-
7
-
-
20544465053
-
Pathological differences in acute inflammatory demyelinating diseases of the central nervous system
-
Wegner, C. Pathological differences in acute inflammatory demyelinating diseases of the central nervous system. Int. MS J. 2005, 12, 13-19.
-
(2005)
Int. MS J
, vol.12
, pp. 13-19
-
-
Wegner, C.1
-
8
-
-
34248650931
-
Passive induction of experimental allergic encephalomyelitis
-
Stromnes, I.M.; Goverman, J.M. Passive induction of experimental allergic encephalomyelitis. Nat. Protoc. 2006, 1, 1952-1960.
-
(2006)
Nat. Protoc
, vol.1
, pp. 1952-1960
-
-
Stromnes, I.M.1
Goverman, J.M.2
-
9
-
-
0033231305
-
Assessment of animal models for MS and demyelinating disease in the design of rational therapy
-
Steinman, L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999, 24, 511-514.
-
(1999)
Neuron
, vol.24
, pp. 511-514
-
-
Steinman, L.1
-
10
-
-
0031891592
-
Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis
-
Molyneux, P.D.; Filippi, M.; Barkhof, F.; Gasperini, C.; Yousry, T.A.; Truyen, L.; Lai, H.M.; Rocca, M.A.; Moseley, I.F.; Miller, D.H. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann. Neurol. 1998, 43, 332-339.
-
(1998)
Ann. Neurol
, vol.43
, pp. 332-339
-
-
Molyneux, P.D.1
Filippi, M.2
Barkhof, F.3
Gasperini, C.4
Yousry, T.A.5
Truyen, L.6
Lai, H.M.7
Rocca, M.A.8
Moseley, I.F.9
Miller, D.H.10
-
11
-
-
0022997935
-
Multiple sclerosis: Gadolinium enhancement in MR imaging
-
Grossman, R.I.; Gonzalez-Scarano, F.; Atlas, S.W.; Galetta, S.; Silberberg, D.H. Multiple sclerosis: Gadolinium enhancement in MR imaging. Radiology 1986, 161, 721-725.
-
(1986)
Radiology
, vol.161
, pp. 721-725
-
-
Grossman, R.I.1
Gonzalez-Scarano, F.2
Atlas, S.W.3
Galetta, S.4
Silberberg, D.H.5
-
12
-
-
84865623132
-
Neuropathologic correlates of magnetic resonance imaging in multiple sclerosis
-
Moore, G.R.; Laule, C. Neuropathologic correlates of magnetic resonance imaging in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2012, 71, 762-778.
-
(2012)
J. Neuropathol. Exp. Neurol
, vol.71
, pp. 762-778
-
-
Moore, G.R.1
Laule, C.2
-
13
-
-
0036189054
-
The role of MRI as a surrogate outcome measure in multiple sclerosis
-
McFarland, H.F.; Barkhof, F.; Antel, J.; Miller, D.H. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult. Scler. 2002, 8, 40-51.
-
(2002)
Mult. Scler
, vol.8
, pp. 40-51
-
-
McFarland, H.F.1
Barkhof, F.2
Antel, J.3
Miller, D.H.4
-
14
-
-
0027521002
-
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group
-
Paty, D.W.; Li, D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993, 43, 662-667.
-
(1993)
Neurology
, vol.43
, pp. 662-667
-
-
Paty, D.W.1
Li, D.K.2
-
15
-
-
0028221168
-
Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: Implications for treatment trials
-
Frank, J.A.; Stone, L.A.; Smith, M.E.; Albert, P.S.; Maloni, H.; McFarland, H.F. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: Implications for treatment trials. Ann. Neurol. 1994, 36, S86-S90.
-
(1994)
Ann. Neurol
, vol.36
-
-
Frank, J.A.1
Stone, L.A.2
Smith, M.E.3
Albert, P.S.4
Maloni, H.5
McFarland, H.F.6
-
16
-
-
0030032466
-
Volumetric measurement of multifocal brain lesions. Implications for treatment trials of vascular dementia and multiple sclerosis
-
Broderick, J.P.; Narayan, S.; Gaskill, M.; Dhawan, A.P.; Khoury, J. Volumetric measurement of multifocal brain lesions. Implications for treatment trials of vascular dementia and multiple sclerosis. J. Neuroimaging 1996, 6, 36-43.
-
(1996)
J. Neuroimaging
, vol.6
, pp. 36-43
-
-
Broderick, J.P.1
Narayan, S.2
Gaskill, M.3
Dhawan, A.P.4
Khoury, J.5
-
17
-
-
0034487603
-
Brain atrophy in relapsing multiple sclerosis: Relationship to relapses, EDSS, and treatment with interferon beta-1a
-
Rudick, R.A.; Fisher, E.; Lee, J.C.; Duda, J.T.; Simon, J. Brain atrophy in relapsing multiple sclerosis: Relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult. Scler. 2000, 6, 365-372.
-
(2000)
Mult. Scler
, vol.6
, pp. 365-372
-
-
Rudick, R.A.1
Fisher, E.2
Lee, J.C.3
Duda, J.T.4
Simon, J.5
-
18
-
-
0034644009
-
The immune system. Second of two parts
-
Delves, P.J.; Roitt, I.M. The immune system. Second of two parts. N. Engl. J. Med. 2000, 343, 108-117.
-
(2000)
N. Engl. J. Med
, vol.343
, pp. 108-117
-
-
Delves, P.J.1
Roitt, I.M.2
-
19
-
-
0029928417
-
The expanding universe of T-cell subsets: Th1, Th2 and more
-
Mosmann, T.R.; Sad, S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 1996, 17, 138-146.
-
(1996)
Immunol. Today
, vol.17
, pp. 138-146
-
-
Mosmann, T.R.1
Sad, S.2
-
20
-
-
33846966636
-
A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage
-
Steinman, L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007, 13, 139-145.
-
(2007)
Nat. Med
, vol.13
, pp. 139-145
-
-
Steinman, L.1
-
21
-
-
0029671318
-
Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)
-
Ferber, I.A.; Brocke, S.; Taylor-Edwards, C.; Ridgway, W.; Dinisco, C.; Steinman, L.; Dalton, D.; Fathman, C.G. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 1996, 156, 5-7.
-
(1996)
J. Immunol
, vol.156
, pp. 5-7
-
-
Ferber, I.A.1
Brocke, S.2
Taylor-Edwards, C.3
Ridgway, W.4
Dinisco, C.5
Steinman, L.6
Dalton, D.7
Fathman, C.G.8
-
22
-
-
37249063841
-
TNFalpha blockade in human diseases: An overview of efficacy and safety
-
Lin, J.; Ziring, D.; Desai, S.; Kim, S.; Wong, M.; Korin, Y.; Braun, J.; Reed, E.; Gjertson, D.; Singh, R.R. TNFalpha blockade in human diseases: An overview of efficacy and safety. Clin. Immunol. 2008, 126, 13-30.
-
(2008)
Clin. Immunol
, vol.126
, pp. 13-30
-
-
Lin, J.1
Ziring, D.2
Desai, S.3
Kim, S.4
Wong, M.5
Korin, Y.6
Braun, J.7
Reed, E.8
Gjertson, D.9
Singh, R.R.10
-
23
-
-
0033546665
-
TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
-
The Lenercept Multiple Sclerosis Study Group; The University of British Columbia MS/MRI Analysis Group
-
The Lenercept Multiple Sclerosis Study Group; The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53, 457-465.
-
(1999)
Neurology
, vol.53
, pp. 457-465
-
-
-
24
-
-
13244283212
-
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
-
Langrish, C.L.; Chen, Y.; Blumenschein, W.M.; Mattson, J.; Basham, B.; Sedgwick, J.D.; McClanahan, T.; Kastelein, R.A.; Cua, D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201, 233-240.
-
(2005)
J. Exp. Med
, vol.201
, pp. 233-240
-
-
Langrish, C.L.1
Chen, Y.2
Blumenschein, W.M.3
Mattson, J.4
Basham, B.5
Sedgwick, J.D.6
McClanahan, T.7
Kastelein, R.A.8
Cua, D.J.9
-
25
-
-
79956152607
-
The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF
-
El-Behi, M.; Ciric, B.; Dai, H.; Yan, Y.; Cullimore, M.; Safavi, F.; Zhang, G.X.; Dittel, B.N.; Rostami, A. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 2011, 12, 568-575.
-
(2011)
Nat. Immunol
, vol.12
, pp. 568-575
-
-
El-Behi, M.1
Ciric, B.2
Dai, H.3
Yan, Y.4
Cullimore, M.5
Safavi, F.6
Zhang, G.X.7
Dittel, B.N.8
Rostami, A.9
-
26
-
-
79956116032
-
RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation
-
Codarri, L.; Gyulveszi, G.; Tosevski, V.; Hesske, L.; Fontana, A.; Magnenat, L.; Suter, T.; Becher, B. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 2011, 12, 560-567.
-
(2011)
Nat. Immunol
, vol.12
, pp. 560-567
-
-
Codarri, L.1
Gyulveszi, G.2
Tosevski, V.3
Hesske, L.4
Fontana, A.5
Magnenat, L.6
Suter, T.7
Becher, B.8
-
27
-
-
33846018916
-
GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis
-
Ponomarev, E.D.; Shriver, L.P.; Maresz, K.; Pedras-Vasconcelos, J.; Verthelyi, D.; Dittel, B.N. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J. Immunol. 2007, 178, 39-48.
-
(2007)
J. Immunol
, vol.178
, pp. 39-48
-
-
Ponomarev, E.D.1
Shriver, L.P.2
Maresz, K.3
Pedras-Vasconcelos, J.4
Verthelyi, D.5
Dittel, B.N.6
-
28
-
-
30944452780
-
Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis
-
Hofstetter, H.H.; Ibrahim, S.M.; Koczan, D.; Kruse, N.; Weishaupt, A.; Toyka, K.V.; Gold, R. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell. Immunol. 2005, 237, 123-130.
-
(2005)
Cell. Immunol
, vol.237
, pp. 123-130
-
-
Hofstetter, H.H.1
Ibrahim, S.M.2
Koczan, D.3
Kruse, N.4
Weishaupt, A.5
Toyka, K.V.6
Gold, R.7
-
29
-
-
33745321276
-
IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis
-
Komiyama, Y.; Nakae, S.; Matsuki, T.; Nambu, A.; Ishigame, H.; Kakuta, S.; Sudo, K.; Iwakura, Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177, 566-573.
-
(2006)
J. Immunol
, vol.177
, pp. 566-573
-
-
Komiyama, Y.1
Nakae, S.2
Matsuki, T.3
Nambu, A.4
Ishigame, H.5
Kakuta, S.6
Sudo, K.7
Iwakura, Y.8
-
30
-
-
56149125346
-
Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis
-
O'Connor, R.A.; Prendergast, C.T.; Sabatos, C.A.; Lau, C.W.; Leech, M.D.; Wraith, D.C.; Anderton, S.M. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 2008, 181, 3750-3754.
-
(2008)
J. Immunol
, vol.181
, pp. 3750-3754
-
-
O'Connor, R.A.1
Prendergast, C.T.2
Sabatos, C.A.3
Lau, C.W.4
Leech, M.D.5
Wraith, D.C.6
Anderton, S.M.7
-
31
-
-
77949973725
-
Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis
-
Kang, Z.; Altuntas, C.Z.; Gulen, M.F.; Liu, C.; Giltiay, N.; Qin, H.; Liu, L.; Qian, W.; Ransohoff, R.M.; Bergmann, C.; et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 2010, 32, 414-425.
-
(2010)
Immunity
, vol.32
, pp. 414-425
-
-
Kang, Z.1
Altuntas, C.Z.2
Gulen, M.F.3
Liu, C.4
Giltiay, N.5
Qin, H.6
Liu, L.7
Qian, W.8
Ransohoff, R.M.9
Bergmann, C.10
-
32
-
-
77950018920
-
Act1, scene brain: Astrocytes play a lead role
-
Rodgers, J.M.; Zhou, L.; Miller, S.D. Act1, scene brain: Astrocytes play a lead role. Immunity 2010, 32, 302-304.
-
(2010)
Immunity
, vol.32
, pp. 302-304
-
-
Rodgers, J.M.1
Zhou, L.2
Miller, S.D.3
-
33
-
-
36949031696
-
SNP mapping and candidate gene sequencing in the class I region of the HLA complex: Searching for multiple sclerosis susceptibility genes in Tasmanians
-
Burfoot, R.K.; Jensen, C.J.; Field, J.; Stankovich, J.; Varney, M.D.; Johnson, L.J.; Butzkueven, H.; Booth, D.; Bahlo, M.; Tait, B.D.; et al. SNP mapping and candidate gene sequencing in the class I region of the HLA complex: Searching for multiple sclerosis susceptibility genes in Tasmanians. Tissue Antigens 2008, 71, 42-50.
-
(2008)
Tissue Antigens
, vol.71
, pp. 42-50
-
-
Burfoot, R.K.1
Jensen, C.J.2
Field, J.3
Stankovich, J.4
Varney, M.D.5
Johnson, L.J.6
Butzkueven, H.7
Booth, D.8
Bahlo, M.9
Tait, B.D.10
-
34
-
-
70149122373
-
Pathogenic CD8(+) T cells in multiple sclerosis
-
Friese, M.A.; Fugger, L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann. Neurol. 2009, 66, 132-141.
-
(2009)
Ann. Neurol
, vol.66
, pp. 132-141
-
-
Friese, M.A.1
Fugger, L.2
-
35
-
-
0036788406
-
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time
-
Kuhlmann, T.; Lingfeld, G.; Bitsch, A.; Schuchardt, J.; Bruck, W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002, 125, 2202-2212.
-
(2002)
Brain
, vol.125
, pp. 2202-2212
-
-
Kuhlmann, T.1
Lingfeld, G.2
Bitsch, A.3
Schuchardt, J.4
Bruck, W.5
-
36
-
-
38749143286
-
Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis
-
Tzartos, J.S.; Friese, M.A.; Craner, M.J.; Palace, J.; Newcombe, J.; Esiri, M.M.; Fugger, L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172, 146-155.
-
(2008)
Am. J. Pathol
, vol.172
, pp. 146-155
-
-
Tzartos, J.S.1
Friese, M.A.2
Craner, M.J.3
Palace, J.4
Newcombe, J.5
Esiri, M.M.6
Fugger, L.7
-
37
-
-
84863116374
-
A transgenic model of central nervous system autoimmunity mediated by CD4(+) and CD8(+) T and B cells
-
Anderson, A.C.; Chandwaskar, R.; Lee, D.H.; Sullivan, J.M.; Solomon, A.; Rodriguez-Manzanet, R.; Greve, B.; Sobel, R.A.; Kuchroo, V.K. A transgenic model of central nervous system autoimmunity mediated by CD4(+) and CD8(+) T and B cells. J. Immunol. 2012, 188, 2084-2092.
-
(2012)
J. Immunol
, vol.188
, pp. 2084-2092
-
-
Anderson, A.C.1
Chandwaskar, R.2
Lee, D.H.3
Sullivan, J.M.4
Solomon, A.5
Rodriguez-Manzanet, R.6
Greve, B.7
Sobel, R.A.8
Kuchroo, V.K.9
-
38
-
-
0036838536
-
Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis
-
Kohm, A.P.; Carpentier, P.A.; Anger, H.A.; Miller, S.D. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 2002, 169, 4712-4716.
-
(2002)
J. Immunol
, vol.169
, pp. 4712-4716
-
-
Kohm, A.P.1
Carpentier, P.A.2
Anger, H.A.3
Miller, S.D.4
-
39
-
-
23744515175
-
Decreased FOXP3 levels in multiple sclerosis patients
-
Huan, J.; Culbertson, N.; Spencer, L.; Bartholomew, R.; Burrows, G.G.; Chou, Y.K.; Bourdette, D.; Ziegler, S.F.; Offner, H.; Vandenbark, A.A. Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res. 2005, 81, 45-52.
-
(2005)
J. Neurosci. Res
, vol.81
, pp. 45-52
-
-
Huan, J.1
Culbertson, N.2
Spencer, L.3
Bartholomew, R.4
Burrows, G.G.5
Chou, Y.K.6
Bourdette, D.7
Ziegler, S.F.8
Offner, H.9
Vandenbark, A.A.10
-
40
-
-
79959770302
-
T regulatory cells are markers of disease activity in multiple sclerosis patients
-
Dalla Libera, D.; di Mitri, D.; Bergami, A.; Centonze, D.; Gasperini, C.; Grasso, M.G.; Galgani, S.; Martinelli, V.; Comi, G.; Avolio, C.; et al. T regulatory cells are markers of disease activity in multiple sclerosis patients. PLoS One 2011, 6, e21386.
-
(2011)
PLoS One
, vol.6
-
-
Dalla, L.D.1
di Mitri, D.2
Bergami, A.3
Centonze, D.4
Gasperini, C.5
Grasso, M.G.6
Galgani, S.7
Martinelli, V.8
Comi, G.9
Avolio, C.10
-
41
-
-
1842607712
-
Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs
-
Putheti, P.; Pettersson, A.; Soderstrom, M.; Link, H.; Huang, Y.M. Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J. Clin. Immunol. 2004, 24, 155-161.
-
(2004)
J. Clin. Immunol
, vol.24
, pp. 155-161
-
-
Putheti, P.1
Pettersson, A.2
Soderstrom, M.3
Link, H.4
Huang, Y.M.5
-
42
-
-
55849126729
-
Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis
-
Michel, L.; Berthelot, L.; Pettre, S.; Wiertlewski, S.; Lefrere, F.; Braudeau, C.; Brouard, S.; Soulillou, J.P.; Laplaud, D.A. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J. Clin. Invest. 2008, 118, 3411-3419.
-
(2008)
J. Clin. Invest
, vol.118
, pp. 3411-3419
-
-
Michel, L.1
Berthelot, L.2
Pettre, S.3
Wiertlewski, S.4
Lefrere, F.5
Braudeau, C.6
Brouard, S.7
Soulillou, J.P.8
Laplaud, D.A.9
-
43
-
-
1842732224
-
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis
-
Viglietta, V.; Baecher-Allan, C.; Weiner, H.L.; Hafler, D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199, 971-979.
-
(2004)
J. Exp. Med
, vol.199
, pp. 971-979
-
-
Viglietta, V.1
Baecher-Allan, C.2
Weiner, H.L.3
Hafler, D.A.4
-
44
-
-
50949124847
-
Human natural killer cells
-
Caligiuri, M.A. Human natural killer cells. Blood 2008, 112, 461-469.
-
(2008)
Blood
, vol.112
, pp. 461-469
-
-
Caligiuri, M.A.1
-
45
-
-
0035874522
-
Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset
-
Cooper, M.A.; Fehniger, T.A.; Turner, S.C.; Chen, K.S.; Ghaheri, B.A.; Ghayur, T.; Carson, W.E.; Caligiuri, M.A. Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001, 97, 3146-3151.
-
(2001)
Blood
, vol.97
, pp. 3146-3151
-
-
Cooper, M.A.1
Fehniger, T.A.2
Turner, S.C.3
Chen, K.S.4
Ghaheri, B.A.5
Ghayur, T.6
Carson, W.E.7
Caligiuri, M.A.8
-
46
-
-
79251497664
-
Presumed guilty: Natural killer T cell defects and human disease
-
Berzins, S.P.; Smyth, M.J.; Baxter, A.G. Presumed guilty: Natural killer T cell defects and human disease. Nat. Rev. Immunol. 2011, 11, 131-142.
-
(2011)
Nat. Rev. Immunol
, vol.11
, pp. 131-142
-
-
Berzins, S.P.1
Smyth, M.J.2
Baxter, A.G.3
-
47
-
-
0018905585
-
Dysfunction of natural killer cells in multiple sclerosis: A possible pathogenetic factor
-
Benczur, M.; Petranyl, G.G.; Palffy, G.; Varga, M.; Talas, M.; Kotsy, B.; Foldes, I.; Hollan, S.R. Dysfunction of natural killer cells in multiple sclerosis: A possible pathogenetic factor. Clin. Exp. Immunol. 1980, 39, 657-662.
-
(1980)
Clin. Exp. Immunol
, vol.39
, pp. 657-662
-
-
Benczur, M.1
Petranyl, G.G.2
Palffy, G.3
Varga, M.4
Talas, M.5
Kotsy, B.6
Foldes, I.7
Hollan, S.R.8
-
48
-
-
0030712367
-
Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells
-
Zhang, B.; Yamamura, T.; Kondo, T.; Fujiwara, M.; Tabira, T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997, 186, 1677-1687.
-
(1997)
J. Exp. Med
, vol.186
, pp. 1677-1687
-
-
Zhang, B.1
Yamamura, T.2
Kondo, T.3
Fujiwara, M.4
Tabira, T.5
-
49
-
-
0020579219
-
Genetic influence on natural cytotoxicity and interferon production in multiple sclerosis studies in monozygotic discordant twins
-
Kaudewitz, P.; Zander, H.; Abb, J.; Ziegler-Heitbrock, H.W.; Riethmuller, G. Genetic influence on natural cytotoxicity and interferon production in multiple sclerosis studies in monozygotic discordant twins. Hum. Immunol. 1983, 7, 51-58.
-
(1983)
Hum. Immunol
, vol.7
, pp. 51-58
-
-
Kaudewitz, P.1
Zander, H.2
Abb, J.3
Ziegler-Heitbrock, H.W.4
Riethmuller, G.5
-
50
-
-
0342906187
-
Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
-
Lucchinetti, C.; Bruck, W.; Parisi, J.; Scheithauer, B.; Rodriguez, M.; Lassmann, H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47, 707-717.
-
(2000)
Ann. Neurol
, vol.47
, pp. 707-717
-
-
Lucchinetti, C.1
Bruck, W.2
Parisi, J.3
Scheithauer, B.4
Rodriguez, M.5
Lassmann, H.6
-
51
-
-
2442708947
-
Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis
-
Serafini, B.; Rosicarelli, B.; Magliozzi, R.; Stigliano, E.; Aloisi, F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14, 164-174.
-
(2004)
Brain Pathol
, vol.14
, pp. 164-174
-
-
Serafini, B.1
Rosicarelli, B.2
Magliozzi, R.3
Stigliano, E.4
Aloisi, F.5
-
52
-
-
34249700046
-
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
-
Magliozzi, R.; Howell, O.; Vora, A.; Serafini, B.; Nicholas, R.; Puopolo, M.; Reynolds, R.; Aloisi, F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130, 1089-1104.
-
(2007)
Brain
, vol.130
, pp. 1089-1104
-
-
Magliozzi, R.1
Howell, O.2
Vora, A.3
Serafini, B.4
Nicholas, R.5
Puopolo, M.6
Reynolds, R.7
Aloisi, F.8
-
53
-
-
79551695835
-
Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis
-
Lovato, L.; Willis, S.N.; Rodig, S.J.; Caron, T.; Almendinger, S.E.; Howell, O.W.; Reynolds, R.; O'Connor, K.C.; Hafler, D.A. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 2011, 134, 534-541.
-
(2011)
Brain
, vol.134
, pp. 534-541
-
-
Lovato, L.1
Willis, S.N.2
Rodig, S.J.3
Caron, T.4
Almendinger, S.E.5
Howell, O.W.6
Reynolds, R.7
O'Connor, K.C.8
Hafler, D.A.9
-
54
-
-
84863196420
-
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude
-
Lechner-Scott, J.; Spencer, B.; de Malmanche, T.; Attia, J.; Fitzgerald, M.; Trojano, M.; Grand'maison, F.; Gomez, J.A.; Izquierdo, G.; Duquette, P.; et al. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Mult. Scler. 2012, 18, 974-982.
-
(2012)
Mult. Scler
, vol.18
, pp. 974-982
-
-
Lechner-Scott, J.1
Spencer, B.2
de Malmanche, T.3
Attia, J.4
Fitzgerald, M.5
Trojano, M.6
Grand'maison, F.7
Gomez, J.A.8
Izquierdo, G.9
Duquette, P.10
-
55
-
-
79953306014
-
Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin
-
Obermeier, B.; Lovato, L.; Mentele, R.; Bruck, W.; Forne, I.; Imhof, A.; Lottspeich, F.; Turk, K.W.; Willis, S.N.; Wekerle, H.; et al. Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J. Neuroimmunol. 2011, 233, 245-248.
-
(2011)
J. Neuroimmunol
, vol.233
, pp. 245-248
-
-
Obermeier, B.1
Lovato, L.2
Mentele, R.3
Bruck, W.4
Forne, I.5
Imhof, A.6
Lottspeich, F.7
Turk, K.W.8
Willis, S.N.9
Wekerle, H.10
-
56
-
-
0026147769
-
Immunopathological recognition of autoantigens in multiple sclerosis
-
Bernard, C.C.; de Rosbo, N.K. Immunopathological recognition of autoantigens in multiple sclerosis. Acta Neurol. (Napoli) 1991, 13, 171-178.
-
(1991)
Acta Neurol. (Napoli)
, vol.13
, pp. 171-178
-
-
Bernard, C.C.1
de Rosbo, N.K.2
-
57
-
-
67650082863
-
Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid
-
Owens, G.P.; Bennett, J.L.; Lassmann, H.; O'Connor, K.C.; Ritchie, A.M.; Shearer, A.; Lam, C.; Yu, X.; Birlea, M.; DuPree, C.; et al Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann. Neurol. 2009, 65, 639-649.
-
(2009)
Ann. Neurol
, vol.65
, pp. 639-649
-
-
Owens, G.P.1
Bennett, J.L.2
Lassmann, H.3
O'Connor, K.C.4
Ritchie, A.M.5
Shearer, A.6
Lam, C.7
Yu, X.8
Birlea, M.9
Dupree, C.10
-
58
-
-
0032950794
-
Identification of autoantibodies associated with myelin damage in multiple sclerosis
-
Genain, C.P.; Cannella, B.; Hauser, S.L.; Raine, C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 1999, 5, 170-175.
-
(1999)
Nat. Med
, vol.5
, pp. 170-175
-
-
Genain, C.P.1
Cannella, B.2
Hauser, S.L.3
Raine, C.S.4
-
59
-
-
84860275553
-
Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis
-
Wootla, B.; Denic, A.; Keegan, B.M.; Winters, J.L.; Astapenko, D.; Warrington, A.E.; Bieber, A.J.; Rodriguez, M. Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis. Neurol. Res. Int. 2011, 2011, 780712.
-
(2011)
Neurol. Res. Int
, vol.2011
, pp. 780712
-
-
Wootla, B.1
Denic, A.2
Keegan, B.M.3
Winters, J.L.4
Astapenko, D.5
Warrington, A.E.6
Bieber, A.J.7
Rodriguez, M.8
-
60
-
-
84859931287
-
The evidence for a role of B cells in multiple sclerosis
-
Disanto, G.; Morahan, J.M.; Barnett, M.H.; Giovannoni, G.; Ramagopalan, S.V. The evidence for a role of B cells in multiple sclerosis. Neurology 2012, 78, 823-832.
-
(2012)
Neurology
, vol.78
, pp. 823-832
-
-
Disanto, G.1
Morahan, J.M.2
Barnett, M.H.3
Giovannoni, G.4
Ramagopalan, S.V.5
-
61
-
-
1642334164
-
Persistence of the Epstein-Barr virus and the origins of associated lymphomas
-
Thorley-Lawson, D.A.; Gross, A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 2004, 350, 1328-1337.
-
(2004)
N. Engl. J. Med
, vol.350
, pp. 1328-1337
-
-
Thorley-Lawson, D.A.1
Gross, A.2
-
62
-
-
34247590137
-
Environmental risk factors for multiple sclerosis. Part I: The role of infection
-
Ascherio, A.; Munger, K.L. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann. Neurol. 2007, 61, 288-299.
-
(2007)
Ann. Neurol
, vol.61
, pp. 288-299
-
-
Ascherio, A.1
Munger, K.L.2
-
63
-
-
33644820800
-
Infectious mononucleosis and risk for multiple sclerosis: A meta-analysis
-
Thacker, E.L.; Mirzaei, F.; Ascherio, A. Infectious mononucleosis and risk for multiple sclerosis: A meta-analysis. Ann. Neurol. 2006, 59, 499-503.
-
(2006)
Ann. Neurol
, vol.59
, pp. 499-503
-
-
Thacker, E.L.1
Mirzaei, F.2
Ascherio, A.3
-
64
-
-
68249150707
-
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI
-
Farrell, R.A.; Antony, D.; Wall, G.R.; Clark, D.A.; Fisniku, L.; Swanton, J.; Khaleeli, Z.; Schmierer, K.; Miller, D.H.; Giovannoni, G. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009, 73, 32-38.
-
(2009)
Neurology
, vol.73
, pp. 32-38
-
-
Farrell, R.A.1
Antony, D.2
Wall, G.R.3
Clark, D.A.4
Fisniku, L.5
Swanton, J.6
Khaleeli, Z.7
Schmierer, K.8
Miller, D.H.9
Giovannoni, G.10
-
65
-
-
0242270822
-
Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases
-
Pender, M.P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 2003, 24, 584-588.
-
(2003)
Trends Immunol
, vol.24
, pp. 584-588
-
-
Pender, M.P.1
-
66
-
-
84867779322
-
CD8+ T-Cell deficiency, epstein-barr virus infection, vitamin D deficiency, and steps to autoimmunity: A unifying hypothesis
-
Pender, M.P. CD8+ T-Cell deficiency, epstein-barr virus infection, vitamin D deficiency, and steps to autoimmunity: A unifying hypothesis. Autoimmune Dis. 2012, 2012, 189096.
-
(2012)
Autoimmune Dis
, vol.2012
, pp. 189096
-
-
Pender, M.P.1
-
67
-
-
84856605958
-
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions
-
Tzartos, J.S.; Khan, G.; Vossenkamper, A.; Cruz-Sadaba, M.; Lonardi, S.; Sefia, E.; Meager, A.; Elia, A.; Middeldorp, J.M.; Clemens, M.; et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012, 78, 15-23.
-
(2012)
Neurology
, vol.78
, pp. 15-23
-
-
Tzartos, J.S.1
Khan, G.2
Vossenkamper, A.3
Cruz-Sadaba, M.4
Lonardi, S.5
Sefia, E.6
Meager, A.7
Elia, A.8
Middeldorp, J.M.9
Clemens, M.10
-
68
-
-
36549034729
-
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain
-
Serafini, B.; Rosicarelli, B.; Franciotta, D.; Magliozzi, R.; Reynolds, R.; Cinque, P.; Andreoni, L.; Trivedi, P.; Salvetti, M.; Faggioni, A., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 2007, 204, 2899-2912.
-
(2007)
J. Exp. Med
, vol.204
, pp. 2899-2912
-
-
Serafini, B.1
Rosicarelli, B.2
Franciotta, D.3
Magliozzi, R.4
Reynolds, R.5
Cinque, P.6
Andreoni, L.7
Trivedi, P.8
Salvetti, M.9
Faggioni, A.10
-
69
-
-
72649104099
-
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain
-
Willis, S.N.; Stadelmann, C.; Rodig, S.J.; Caron, T.; Gattenloehner, S.; Mallozzi, S.S.; Roughan, J.E.; Almendinger, S.E.; Blewett, M.M.; Bruck, W., et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009, 132, 3318-3328.
-
(2009)
Brain
, vol.132
, pp. 3318-3328
-
-
Willis, S.N.1
Stadelmann, C.2
Rodig, S.J.3
Caron, T.4
Gattenloehner, S.5
Mallozzi, S.S.6
Roughan, J.E.7
Almendinger, S.E.8
Blewett, M.M.9
Bruck, W.10
-
70
-
-
77951021143
-
Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis
-
Sargsyan, S.A.; Shearer, A.J.; Ritchie, A.M.; Burgoon, M.P.; Anderson, S.; Hemmer, B.; Stadelmann, C.; Gattenlohner, S.; Owens, G.P.; Gilden, D., et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010, 74, 1127-1135.
-
(2010)
Neurology
, vol.74
, pp. 1127-1135
-
-
Sargsyan, S.A.1
Shearer, A.J.2
Ritchie, A.M.3
Burgoon, M.P.4
Anderson, S.5
Hemmer, B.6
Stadelmann, C.7
Gattenlohner, S.8
Owens, G.P.9
Gilden, D.10
-
71
-
-
0036793245
-
A functional and structural basis for TCR cross-reactivity in multiple sclerosis
-
Lang, H.L.; Jacobsen, H.; Ikemizu, S.; Andersson, C.; Harlos, K.; Madsen, L.; Hjorth, P.; Sondergaard, L.; Svejgaard, A.; Wucherpfennig, K., et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 2002, 3, 940-943.
-
(2002)
Nat. Immunol
, vol.3
, pp. 940-943
-
-
Lang, H.L.1
Jacobsen, H.2
Ikemizu, S.3
Andersson, C.4
Harlos, K.5
Madsen, L.6
Hjorth, P.7
Sondergaard, L.8
Svejgaard, A.9
Wucherpfennig, K.10
-
72
-
-
0020262337
-
Immortalization of human lymphocytes by Epstein-Barr virus
-
Miller, G. Immortalization of human lymphocytes by Epstein-Barr virus. Yale J. Biol. Med. 1982, 55, 305-310.
-
(1982)
Yale J. Biol. Med
, vol.55
, pp. 305-310
-
-
Miller, G.1
-
73
-
-
78650996077
-
A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis
-
Ray, A.; Mann, M.K.; Basu, S.; Dittel, B.N. A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Neuroimmunol. 2011, 230, 1-9.
-
(2011)
J. Neuroimmunol
, vol.230
, pp. 1-9
-
-
Ray, A.1
Mann, M.K.2
Basu, S.3
Dittel, B.N.4
-
74
-
-
39049142995
-
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
-
Hauser, S.L.; Waubant, E.; Arnold, D.L.; Vollmer, T.; Antel, J.; Fox, R.J.; Bar-Or, A.; Panzara, M.; Sarkar, N.; Agarwal, S., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358, 676-688.
-
(2008)
N. Engl. J. Med
, vol.358
, pp. 676-688
-
-
Hauser, S.L.1
Waubant, E.2
Arnold, D.L.3
Vollmer, T.4
Antel, J.5
Fox, R.J.6
Bar-Or, A.7
Panzara, M.8
Sarkar, N.9
Agarwal, S.10
-
75
-
-
41849116363
-
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
-
Bar-Or, A.; Calabresi, P.A.; Arnold, D.; Markowitz, C.; Shafer, S.; Kasper, L.H.; Waubant, E.; Gazda, S.; Fox, R.J.; Panzara, M., et al. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann. Neurol. 2008, 63, 395-400.
-
(2008)
Ann. Neurol
, vol.63
, pp. 395-400
-
-
Bar-Or, A.1
Calabresi, P.A.2
Arnold, D.3
Markowitz, C.4
Shafer, S.5
Kasper, L.H.6
Waubant, E.7
Gazda, S.8
Fox, R.J.9
Panzara, M.10
-
76
-
-
77953335494
-
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
-
Naismith, R.T.; Piccio, L.; Lyons, J.A.; Lauber, J.; Tutlam, N.T.; Parks, B.J.; Trinkaus, K.; Song, S.K.; Cross, A.H. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology 2010, 74, 1860-1867.
-
(2010)
Neurology
, vol.74
, pp. 1860-1867
-
-
Naismith, R.T.1
Piccio, L.2
Lyons, J.A.3
Lauber, J.4
Tutlam, N.T.5
Parks, B.J.6
Trinkaus, K.7
Song, S.K.8
Cross, A.H.9
-
77
-
-
49149111862
-
Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis
-
Harp, C.T.; Lovett-Racke, A.E.; Racke, M.K.; Frohman, E.M.; Monson, N.L. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin. Immunol. 2008, 128, 382-391.
-
(2008)
Clin. Immunol
, vol.128
, pp. 382-391
-
-
Harp, C.T.1
Lovett-Racke, A.E.2
Racke, M.K.3
Frohman, E.M.4
Monson, N.L.5
-
78
-
-
77951757865
-
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
-
Bar-Or, A.; Fawaz, L.; Fan, B.; Darlington, P.J.; Rieger, A.; Ghorayeb, C.; Calabresi, P.A.; Waubant, E.; Hauser, S.L.; Zhang, J., et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann. Neurol. 2010, 67, 452-461.
-
(2010)
Ann. Neurol
, vol.67
, pp. 452-461
-
-
Bar-Or, A.1
Fawaz, L.2
Fan, B.3
Darlington, P.J.4
Rieger, A.5
Ghorayeb, C.6
Calabresi, P.A.7
Waubant, E.8
Hauser, S.L.9
Zhang, J.10
-
79
-
-
0030970058
-
Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis
-
Benveniste, E.N. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med. (Berl) 1997, 75, 165-173.
-
(1997)
J. Mol. Med. (Berl)
, vol.75
, pp. 165-173
-
-
Benveniste, E.N.1
-
80
-
-
0031002545
-
Axonal damage in acute multiple sclerosis lesions
-
Ferguson, B.; Matyszak, M.K.; Esiri, M.M.; Perry, V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120, 393-399.
-
(1997)
Brain
, vol.120
, pp. 393-399
-
-
Ferguson, B.1
Matyszak, M.K.2
Esiri, M.M.3
Perry, V.H.4
-
81
-
-
66549130329
-
The relation between inflammation and neurodegeneration in multiple sclerosis brains
-
Frischer, J.M.; Bramow, S.; Dal-Bianco, A.; Lucchinetti, C.F.; Rauschka, H.; Schmidbauer, M.; Laursen, H.; Sorensen, P.S.; Lassmann, H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132, 1175-1189.
-
(2009)
Brain
, vol.132
, pp. 1175-1189
-
-
Frischer, J.M.1
Bramow, S.2
Dal-Bianco, A.3
Lucchinetti, C.F.4
Rauschka, H.5
Schmidbauer, M.6
Laursen, H.7
Sorensen, P.S.8
Lassmann, H.9
-
82
-
-
0032703087
-
Is there a balance between microglia and astrocytes in regulating Th1/Th2-cell responses and neuropathologies?
-
Xiao, B.G.; Link, H. Is there a balance between microglia and astrocytes in regulating Th1/Th2-cell responses and neuropathologies? Immunol. Today 1999, 20, 477-479.
-
(1999)
Immunol. Today
, vol.20
, pp. 477-479
-
-
Xiao, B.G.1
Link, H.2
-
83
-
-
0028964455
-
The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions
-
De Simone, R.; Giampaolo, A.; Giometto, B.; Gallo, P.; Levi, G.; Peschle, C.; Aloisi, F. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J. Neuropathol. Exp. Neurol. 1995, 54, 175-187.
-
(1995)
J. Neuropathol. Exp. Neurol
, vol.54
, pp. 175-187
-
-
de Simone, R.1
Giampaolo, A.2
Giometto, B.3
Gallo, P.4
Levi, G.5
Peschle, C.6
Aloisi, F.7
-
84
-
-
0028941871
-
The adhesion molecule and cytokine profile of multiple sclerosis lesions
-
Cannella, B.; Raine, C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995, 37, 424-435.
-
(1995)
Ann. Neurol
, vol.37
, pp. 424-435
-
-
Cannella, B.1
Raine, C.S.2
-
85
-
-
0029078126
-
Tumor necrosis factor-alpha production by human fetal microglial cells: Regulation by other cytokines
-
Chao, C.C.; Hu, S.; Sheng, W.S.; Peterson, P.K. Tumor necrosis factor-alpha production by human fetal microglial cells: Regulation by other cytokines. Dev. Neurosci. 1995, 17, 97-105.
-
(1995)
Dev. Neurosci
, vol.17
, pp. 97-105
-
-
Chao, C.C.1
Hu, S.2
Sheng, W.S.3
Peterson, P.K.4
-
86
-
-
0027161216
-
Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide
-
Merrill, J.E.; Ignarro, L.J.; Sherman, M.P.; Melinek, J.; Lane, T.E. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 1993, 151, 2132-2141.
-
(1993)
J. Immunol
, vol.151
, pp. 2132-2141
-
-
Merrill, J.E.1
Ignarro, L.J.2
Sherman, M.P.3
Melinek, J.4
Lane, T.E.5
-
87
-
-
0018098512
-
Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis
-
Prineas, J.W.; Wright, R.G. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. 1978, 38, 409-421.
-
(1978)
Lab. Invest
, vol.38
, pp. 409-421
-
-
Prineas, J.W.1
Wright, R.G.2
-
88
-
-
0018965062
-
Nature of the reversible white matter lesion in multiple sclerosis. Effects of acute inflammation on myelinated tissue studied in the rabbit eye
-
Dalakas, M.; Wright, R.G.; Prineas, J.W. Nature of the reversible white matter lesion in multiple sclerosis. Effects of acute inflammation on myelinated tissue studied in the rabbit eye. Brain 1980, 103, 515-524.
-
(1980)
Brain
, vol.103
, pp. 515-524
-
-
Dalakas, M.1
Wright, R.G.2
Prineas, J.W.3
-
89
-
-
0032080456
-
Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis
-
Walsh, M.J.; Murray, J.M. Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis. J. Clin. Invest. 1998, 101, 1923-1931.
-
(1998)
J. Clin. Invest
, vol.101
, pp. 1923-1931
-
-
Walsh, M.J.1
Murray, J.M.2
-
90
-
-
22844445230
-
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
-
Langer-Gould, A.; Atlas, S.W.; Green, A.J.; Bollen, A.W.; Pelletier, D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 2005, 353, 375-381.
-
(2005)
N. Engl. J. Med
, vol.353
, pp. 375-381
-
-
Langer-Gould, A.1
Atlas, S.W.2
Green, A.J.3
Bollen, A.W.4
Pelletier, D.5
-
91
-
-
0008678962
-
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
-
Jacobs, L.D.; Cookfair, D.L.; Rudick, R.A.; Herndon, R.M.; Richert, J.R.; Salazar, A.M.; Fischer, J.S.; Goodkin, D.E.; Granger, C.V.; Simon, J.H., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 1996, 39, 285-294.
-
(1996)
Ann. Neurol
, vol.39
, pp. 285-294
-
-
Jacobs, L.D.1
Cookfair, D.L.2
Rudick, R.A.3
Herndon, R.M.4
Richert, J.R.5
Salazar, A.M.6
Fischer, J.S.7
Goodkin, D.E.8
Granger, C.V.9
Simon, J.H.10
-
92
-
-
0345601517
-
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
-
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group
-
Ebers, G.C.; PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352, 1498-1504.
-
(1998)
Lancet
, vol.352
, pp. 1498-1504
-
-
Ebers, G.C.1
-
93
-
-
0027418515
-
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
-
The IFNB Multiple Sclerosis Study Group
-
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43, 655-661.
-
(1993)
Neurology
, vol.43
, pp. 655-661
-
-
-
94
-
-
8544249096
-
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)
-
Rudick, R.A.; Goodkin, D.E.; Jacobs, L.D.; Cookfair, D.L.; Herndon, R.M.; Richert, J.R.; Salazar, A.M.; Fischer, J.S.; Granger, C.V.; Simon, J.H., et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997, 49, 358-363.
-
(1997)
Neurology
, vol.49
, pp. 358-363
-
-
Rudick, R.A.1
Goodkin, D.E.2
Jacobs, L.D.3
Cookfair, D.L.4
Herndon, R.M.5
Richert, J.R.6
Salazar, A.M.7
Fischer, J.S.8
Granger, C.V.9
Simon, J.H.10
-
95
-
-
0029082566
-
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial
-
Johnson, K.P.; Brooks, B.R.; Cohen, J.A.; Ford, C.C.; Goldstein, J.; Lisak, R.P.; Myers, L.W.; Panitch, H.S.; Rose, J.W.; Schiffer, R.B., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995, 45, 1268-1276.
-
(1995)
Neurology
, vol.45
, pp. 1268-1276
-
-
Johnson, K.P.1
Brooks, B.R.2
Cohen, J.A.3
Ford, C.C.4
Goldstein, J.5
Lisak, R.P.6
Myers, L.W.7
Panitch, H.S.8
Rose, J.W.9
Schiffer, R.B.10
-
96
-
-
33644584352
-
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
-
Polman, C.H.; O'Connor, P.W.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, D.H.; Phillips, J.T.; Lublin, F.D.; Giovannoni, G.; Wajgt, A., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354, 899-910.
-
(2006)
N. Engl. J. Med
, vol.354
, pp. 899-910
-
-
Polman, C.H.1
O'Connor, P.W.2
Havrdova, E.3
Hutchinson, M.4
Kappos, L.5
Miller, D.H.6
Phillips, J.T.7
Lublin, F.D.8
Giovannoni, G.9
Wajgt, A.10
-
97
-
-
76149093586
-
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
-
Kappos, L.; Radue, E.W.; O'Connor, P.; Polman, C.; Hohlfeld, R.; Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson, L., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362, 387-401.
-
(2010)
N. Engl. J. Med
, vol.362
, pp. 387-401
-
-
Kappos, L.1
Radue, E.W.2
O'Connor, P.3
Polman, C.4
Hohlfeld, R.5
Calabresi, P.6
Selmaj, K.7
Agoropoulou, C.8
Leyk, M.9
Zhang-Auberson, L.10
-
98
-
-
79956024142
-
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: A randomised extension of the TRANSFORMS study
-
Khatri, B.; Barkhof, F.; Comi, G.; Hartung, H.P.; Kappos, L.; Montalban, X.; Pelletier, J.; Stites, T.; Wu, S.; Holdbrook, F., et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: A randomised extension of the TRANSFORMS study. Lancet Neurol. 2011, 10, 520-529.
-
(2011)
Lancet Neurol
, vol.10
, pp. 520-529
-
-
Khatri, B.1
Barkhof, F.2
Comi, G.3
Hartung, H.P.4
Kappos, L.5
Montalban, X.6
Pelletier, J.7
Stites, T.8
Wu, S.9
Holdbrook, F.10
-
99
-
-
84867825704
-
-
Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study. Available online, accessed on 18 September 2012
-
Fox, R. Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study. Available online: http://www.abstracts2view.com/aan/view.php?nu=AAN12L_S01_003 (accessed on 18 September 2012).
-
-
-
Fox, R.1
-
101
-
-
84867784484
-
Safety and Tolerability of BG-12 in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Analyses from the CONFIRM Study
-
New Orleans, LA, USA, 21-28 April
-
Phillips, J.T.; Fox, L.M.; Miller, D.C.; Kita, M.; Hutchinson, M.; Havrdova, E.; Raghupathi, K.; Yuan, H.; Novas, M.; Viglietta, V., et al. Safety and Tolerability of BG-12 in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Analyses from the CONFIRM Study. In Proceedings of American Academy of Neurology, New Orleans, LA, USA, 21-28 April 2012.
-
(2012)
Proceedings of American Academy of Neurology
-
-
Phillips, J.T.1
Fox, L.M.2
Miller, D.C.3
Kita, M.4
Hutchinson, M.5
Havrdova, E.6
Raghupathi, K.7
Yuan, H.8
Novas, M.9
Viglietta, V.10
-
102
-
-
80053533877
-
Randomized trial of oral teriflunomide for relapsing multiple sclerosis
-
O'Connor, P.; Wolinsky, J.S.; Confavreux, C.; Comi, G.; Kappos, L.; Olsson, T.P.; Benzerdjeb, H.; Truffinet, P.; Wang, L.; Miller, A.; et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 2011, 365, 1293-1303.
-
(2011)
N. Engl. J. Med
, vol.365
, pp. 1293-1303
-
-
O'Connor, P.1
Wolinsky, J.S.2
Confavreux, C.3
Comi, G.4
Kappos, L.5
Olsson, T.P.6
Benzerdjeb, H.7
Truffinet, P.8
Wang, L.9
Miller, A.10
-
103
-
-
84858217865
-
Placebo-controlled trial of oral laquinimod for multiple sclerosis
-
Comi, G.; Jeffery, D.; Kappos, L.; Montalban, X.; Boyko, A.; Rocca, M.A.; Filippi, M. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 2012, 366, 1000-1009.
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 1000-1009
-
-
Comi, G.1
Jeffery, D.2
Kappos, L.3
Montalban, X.4
Boyko, A.5
Rocca, M.A.6
Filippi, M.7
-
104
-
-
84872063167
-
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy
-
New Orleans, LA, USA, 21-28 April, Vol. S01.004
-
Cohen, J.A. Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy. In Proceedings of American Academy of Neurology (AAN), New Orleans, LA, USA, 21-28 April,2012; Vol. S01.004.
-
(2012)
Proceedings of American Academy of Neurology (AAN)
-
-
Cohen, J.A.1
-
105
-
-
84867779283
-
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naïve Patients
-
New Orleans, LA, USA, 21-28 April, Volume S01.006
-
Coles, A.J. Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naïve Patients. In Proceedings of American Academy of Neurology, New Orleans, LA, USA, 21-28 April,2012; Volume S01.006.
-
(2012)
Proceedings of American Academy of Neurology
-
-
Coles, A.J.1
-
106
-
-
82355181854
-
Establishing long-term efficacy in chronic disease: Use of recursive partitioning and propensity score adjustment to estimate outcome in MS
-
Goodin, D.S.; Jones, J.; Li, D.; Traboulsee, A.; Reder, A.T.; Beckmann, K.; Konieczny, A.; Knappertz, V. Establishing long-term efficacy in chronic disease: Use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One 2011, 6, e22444.
-
(2011)
PLoS One
, vol.6
-
-
Goodin, D.S.1
Jones, J.2
Li, D.3
Traboulsee, A.4
Reder, A.T.5
Beckmann, K.6
Konieczny, A.7
Knappertz, V.8
-
107
-
-
84863895902
-
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis
-
Shirani, A.; Zhao, Y.; Karim, M.E.; Evans, C.; Kingwell, E.; van der Kop, M.L.; Oger, J.; Gustafson, P.; Petkau, J.; Tremlett, H. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012, 308, 247-256.
-
(2012)
JAMA
, vol.308
, pp. 247-256
-
-
Shirani, A.1
Zhao, Y.2
Karim, M.E.3
Evans, C.4
Kingwell, E.5
van der Kop, M.L.6
Oger, J.7
Gustafson, P.8
Petkau, J.9
Tremlett, H.10
-
108
-
-
33745070952
-
Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by bystander activation
-
McCoy, L.; Tsunoda, I.; Fujinami, R.S. Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 2006, 39, 9-19.
-
(2006)
Autoimmunity
, vol.39
, pp. 9-19
-
-
McCoy, L.1
Tsunoda, I.2
Fujinami, R.S.3
-
109
-
-
1642378949
-
Interferons and interferon inhibitory activity in disease and therapy
-
Chadha, K.C.; Ambrus, J.L., Jr.; Dembinski, W.; Ambrus, J.L., Sr. Interferons and interferon inhibitory activity in disease and therapy. Exp. Biol. Med. (Maywood) 2004, 229, 285-290.
-
(2004)
Exp. Biol. Med. (Maywood)
, vol.229
, pp. 285-290
-
-
Chadha, K.C.1
Ambrus Jr., J.L.2
Dembinski, W.3
Ambrus Sr., J.L.4
-
110
-
-
0033544319
-
Interferon beta induces T-helper 2 immune deviation in MS
-
Kozovska, M.E.; Hong, J.; Zang, Y.C.; Li, S.; Rivera, V.M.; Killian, J.M.; Zhang, J.Z. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999, 53, 1692-1697.
-
(1999)
Neurology
, vol.53
, pp. 1692-1697
-
-
Kozovska, M.E.1
Hong, J.2
Zang, Y.C.3
Li, S.4
Rivera, V.M.5
Killian, J.M.6
Zhang, J.Z.7
-
111
-
-
0035212758
-
Immunomodulatory effects of interferon beta-1a in multiple sclerosis
-
Liu, Z.; Pelfrey, C.M.; Cotleur, A.; Lee, J.C.; Rudick, R.A. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J. Neuroimmunol. 2001, 112, 153-162.
-
(2001)
J. Neuroimmunol
, vol.112
, pp. 153-162
-
-
Liu, Z.1
Pelfrey, C.M.2
Cotleur, A.3
Lee, J.C.4
Rudick, R.A.5
-
112
-
-
0032977543
-
Multiple sclerosis: Levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment
-
Ozenci, V.; Kouwenhoven, M.; Huang, Y.M.; Xiao, B.; Kivisakk, P.; Fredrikson, S.; Link, H. Multiple sclerosis: Levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment. Scand. J. Immunol. 1999, 49, 554-561.
-
(1999)
Scand. J. Immunol
, vol.49
, pp. 554-561
-
-
Ozenci, V.1
Kouwenhoven, M.2
Huang, Y.M.3
Xiao, B.4
Kivisakk, P.5
Fredrikson, S.6
Link, H.7
-
113
-
-
70349257850
-
Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS
-
Chen, M.; Chen, G.; Nie, H.; Zhang, X.; Niu, X.; Zang, Y.C.; Skinner, S.M.; Zhang, J.Z.; Killian, J.M.; Hong, J. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. Eur. J. Immunol. 2009, 39, 2525-2536.
-
(2009)
Eur. J. Immunol
, vol.39
, pp. 2525-2536
-
-
Chen, M.1
Chen, G.2
Nie, H.3
Zhang, X.4
Niu, X.5
Zang, Y.C.6
Skinner, S.M.7
Zhang, J.Z.8
Killian, J.M.9
Hong, J.10
-
114
-
-
82755165048
-
Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation
-
Zhang, L.; Yuan, S.; Cheng, G.; Guo, B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS One 2011, 6, e28432.
-
(2011)
PLoS One
, vol.6
-
-
Zhang, L.1
Yuan, S.2
Cheng, G.3
Guo, B.4
-
115
-
-
43049101640
-
The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice
-
Guo, B.; Chang, E.Y.; Cheng, G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 2008, 118, 1680-1690.
-
(2008)
J. Clin. Invest
, vol.118
, pp. 1680-1690
-
-
Guo, B.1
Chang, E.Y.2
Cheng, G.3
-
116
-
-
44449146212
-
Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: Role of intracellular osteopontin
-
Shinohara, M.L.; Kim, J.H.; Garcia, V.A.; Cantor, H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: Role of intracellular osteopontin. Immunity 2008, 29, 68-78.
-
(2008)
Immunity
, vol.29
, pp. 68-78
-
-
Shinohara, M.L.1
Kim, J.H.2
Garcia, V.A.3
Cantor, H.4
-
117
-
-
77950526192
-
IFN-beta inhibits human Th17 cell differentiation
-
Ramgolam, V.S.; Sha, Y.; Jin, J.; Zhang, X.; Markovic-Plese, S. IFN-beta inhibits human Th17 cell differentiation. J. Immunol. 2009, 183, 5418-5427.
-
(2009)
J. Immunol
, vol.183
, pp. 5418-5427
-
-
Ramgolam, V.S.1
Sha, Y.2
Jin, J.3
Zhang, X.4
Markovic-Plese, S.5
-
118
-
-
79958108785
-
The mechanism of action of interferon-beta in relapsing multiple sclerosis
-
Kieseier, B.C. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 2011, 25, 491-502.
-
(2011)
CNS Drugs
, vol.25
, pp. 491-502
-
-
Kieseier, B.C.1
-
119
-
-
34447290007
-
Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta
-
Saraste, M.; Irjala, H.; Airas, L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol. Sci. 2007, 28, 121-126.
-
(2007)
Neurol. Sci
, vol.28
, pp. 121-126
-
-
Saraste, M.1
Irjala, H.2
Airas, L.3
-
120
-
-
70349741303
-
Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis
-
Vandenbark, A.A.; Huan, J.; Agotsch, M.; La Tocha, D.; Goelz, S.; Offner, H.; Lanker, S.; Bourdette, D. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J. Neuroimmunol. 2009, 215, 125-128.
-
(2009)
J. Neuroimmunol
, vol.215
, pp. 125-128
-
-
Vandenbark, A.A.1
Huan, J.2
Agotsch, M.3
la Tocha, D.4
Goelz, S.5
Offner, H.6
Lanker, S.7
Bourdette, D.8
-
121
-
-
79960197977
-
Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-beta and interferon-beta combined with low-dose oral steroids
-
Sanvito, L.; Tomita, A.; Chihara, N.; Okamoto, T.; Lin, Y.; Ogawa, M.; Gran, B.; Aranami, T.; Yamamura, T. Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-beta and interferon-beta combined with low-dose oral steroids. J. Neuroimmunol. 2011, 236, 111-117.
-
(2011)
J. Neuroimmunol
, vol.236
, pp. 111-117
-
-
Sanvito, L.1
Tomita, A.2
Chihara, N.3
Okamoto, T.4
Lin, Y.5
Ogawa, M.6
Gran, B.7
Aranami, T.8
Yamamura, T.9
-
122
-
-
81355160418
-
Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis
-
Martinez-Rodriguez, J.E.; Lopez-Botet, M.; Munteis, E.; Rio, J.; Roquer, J.; Montalban, X.; Comabella, M. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin. Immunol. 2011, 141, 348-356.
-
(2011)
Clin. Immunol
, vol.141
, pp. 348-356
-
-
Martinez-Rodriguez, J.E.1
Lopez-Botet, M.2
Munteis, E.3
Rio, J.4
Roquer, J.5
Montalban, X.6
Comabella, M.7
-
123
-
-
33845873044
-
Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: An ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis
-
De Andres, C.; Aristimuno, C.; de Las Heras, V.; Martinez-Gines, M.L.; Bartolome, M.; Arroyo, R.; Navarro, J.; Gimenez-Roldan, S.; Fernandez-Cruz, E.; Sanchez-Ramon, S. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: An ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 2007, 182, 204-211.
-
(2007)
J. Neuroimmunol
, vol.182
, pp. 204-211
-
-
de Andres, C.1
Aristimuno, C.2
de las Heras, V.3
Martinez-Gines, M.L.4
Bartolome, M.5
Arroyo, R.6
Navarro, J.7
Gimenez-Roldan, S.8
Fernandez-Cruz, E.9
Sanchez-Ramon, S.10
-
124
-
-
55949119602
-
Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells
-
Korporal, M.; Haas, J.; Balint, B.; Fritzsching, B.; Schwarz, A.; Moeller, S.; Fritz, B.; Suri-Payer, E.; Wildemann, B. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch. Neurol. 2008, 65, 1434-1439.
-
(2008)
Arch. Neurol
, vol.65
, pp. 1434-1439
-
-
Korporal, M.1
Haas, J.2
Balint, B.3
Fritzsching, B.4
Schwarz, A.5
Moeller, S.6
Fritz, B.7
Suri-Payer, E.8
Wildemann, B.9
-
125
-
-
84856805188
-
IFN-beta induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis
-
Chen, M.; Chen, G.; Deng, S.; Liu, X.; Hutton, G.J.; Hong, J. IFN-beta induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J. Neuroimmunol. 2012, 242, 39-46.
-
(2012)
J. Neuroimmunol
, vol.242
, pp. 39-46
-
-
Chen, M.1
Chen, G.2
Deng, S.3
Liu, X.4
Hutton, G.J.5
Hong, J.6
-
126
-
-
29444451569
-
Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy
-
Caggiula, M.; Batocchi, A.P.; Frisullo, G.; Angelucci, F.; Patanella, A.K.; Sancricca, C.; Nociti, V.; Tonali, P.A.; Mirabella, M. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin. Immunol. 2006, 118, 77-82.
-
(2006)
Clin. Immunol
, vol.118
, pp. 77-82
-
-
Caggiula, M.1
Batocchi, A.P.2
Frisullo, G.3
Angelucci, F.4
Patanella, A.K.5
Sancricca, C.6
Nociti, V.7
Tonali, P.A.8
Mirabella, M.9
-
127
-
-
0030756916
-
Interferon-beta is a potent promoter of nerve growth factor production by astrocytes
-
Boutros, T.; Croze, E.; Yong, V.W. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. J. Neurochem. 1997, 69, 939-946.
-
(1997)
J. Neurochem
, vol.69
, pp. 939-946
-
-
Boutros, T.1
Croze, E.2
Yong, V.W.3
-
128
-
-
16844385713
-
Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis
-
Biernacki, K.; Antel, J.P.; Blain, M.; Narayanan, S.; Arnold, D.L.; Prat, A. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol. 2005, 62, 563-568.
-
(2005)
Arch. Neurol
, vol.62
, pp. 563-568
-
-
Biernacki, K.1
Antel, J.P.2
Blain, M.3
Narayanan, S.4
Arnold, D.L.5
Prat, A.6
-
129
-
-
79954997896
-
B cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis
-
Ramgolam, V.S.; Sha, Y.; Marcus, K.L.; Choudhary, N.; Troiani, L.; Chopra, M.; Markovic-Plese, S. B cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis. J. Immunol. 2011, 186, 4518-4526.
-
(2011)
J. Immunol
, vol.186
, pp. 4518-4526
-
-
Ramgolam, V.S.1
Sha, Y.2
Marcus, K.L.3
Choudhary, N.4
Troiani, L.5
Chopra, M.6
Markovic-Plese, S.7
-
130
-
-
72149122640
-
Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: Design and lessons from a 16-year observational study
-
Ebers, G.C.; Reder, A.T.; Traboulsee, A.; Li, D.; Langdon, D.; Goodin, D.S.; Wolf, C.; Beckmann, K.; Konieczny, A. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: Design and lessons from a 16-year observational study. Clin. Ther. 2009, 31, 1724-1736.
-
(2009)
Clin. Ther
, vol.31
, pp. 1724-1736
-
-
Ebers, G.C.1
Reder, A.T.2
Traboulsee, A.3
Li, D.4
Langdon, D.5
Goodin, D.S.6
Wolf, C.7
Beckmann, K.8
Konieczny, A.9
-
131
-
-
84862736347
-
Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?
-
doi:10.1177/1352458512439439
-
Kim, S.H.; Kim, W.; Li, X.F.; Jung, I.J.; Kim, H.J. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult. Scler. 2012, doi:10.1177/1352458512439439.
-
(2012)
Mult. Scler
-
-
Kim, S.H.1
Kim, W.2
Li, X.F.3
Jung, I.J.4
Kim, H.J.5
-
132
-
-
77950534540
-
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis
-
Axtell, R.C.; de Jong, B.A.; Boniface, K.; van der Voort, L.F.; Bhat, R.; de Sarno, P.; Naves, R.; Han, M.; Zhong, F.; Castellanos, J.G., et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 2010, 16, 406-412.
-
(2010)
Nat. Med
, vol.16
, pp. 406-412
-
-
Axtell, R.C.1
de Jong, B.A.2
Boniface, K.3
van der Voort, L.F.4
Bhat, R.5
de Sarno, P.6
Naves, R.7
Han, M.8
Zhong, F.9
Castellanos, J.G.10
-
133
-
-
84862741487
-
Serum IL-17F does not predict poor response to IM IFNbeta-1a in relapsing-remitting MS
-
Bushnell, S.E.; Zhao, Z.; Stebbins, C.C.; Cadavid, D.; Buko, A.M.; Whalley, E.T.; Davis, J.A.; Versage, E.M.; Richert, J.R.; Axtell, R.C., et al. Serum IL-17F does not predict poor response to IM IFNbeta-1a in relapsing-remitting MS. Neurology 2012, 79, 531-537.
-
(2012)
Neurology
, vol.79
, pp. 531-537
-
-
Bushnell, S.E.1
Zhao, Z.2
Stebbins, C.C.3
Cadavid, D.4
Buko, A.M.5
Whalley, E.T.6
Davis, J.A.7
Versage, E.M.8
Richert, J.R.9
Axtell, R.C.10
-
134
-
-
0034936777
-
Glatiramer acetate in the treatment of multiple sclerosis
-
Sela, M.; Teitelbaum, D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin. Pharmacother. 2001, 2, 1149-1165.
-
(2001)
Expert Opin. Pharmacother
, vol.2
, pp. 1149-1165
-
-
Sela, M.1
Teitelbaum, D.2
-
135
-
-
0023248694
-
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis
-
Bornstein, M.B.; Miller, A.; Slagle, S.; Weitzman, M.; Crystal, H.; Drexler, E.; Keilson, M.; Merriam, A.; Wassertheil-Smoller, S.; Spada, V., et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. 1987, 317, 408-414.
-
(1987)
N. Engl. J. Med
, vol.317
, pp. 408-414
-
-
Bornstein, M.B.1
Miller, A.2
Slagle, S.3
Weitzman, M.4
Crystal, H.5
Drexler, E.6
Keilson, M.7
Merriam, A.8
Wassertheil-Smoller, S.9
Spada, V.10
-
136
-
-
0035091667
-
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
-
Comi, G.; Filippi, M.; Wolinsky, J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann. Neurol. 2001, 49, 290-297.
-
(2001)
Ann. Neurol
, vol.49
, pp. 290-297
-
-
Comi, G.1
Filippi, M.2
Wolinsky, J.S.3
-
137
-
-
51449101000
-
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial
-
Mikol, D.D.; Barkhof, F.; Chang, P.; Coyle, P.K.; Jeffery, D.R.; Schwid, S.R.; Stubinski, B.; Uitdehaag, B.M. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008, 7, 903-914.
-
(2008)
Lancet Neurol
, vol.7
, pp. 903-914
-
-
Mikol, D.D.1
Barkhof, F.2
Chang, P.3
Coyle, P.K.4
Jeffery, D.R.5
Schwid, S.R.6
Stubinski, B.7
Uitdehaag, B.M.8
-
138
-
-
69949098534
-
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study
-
O'Connor, P.; Filippi, M.; Arnason, B.; Comi, G.; Cook, S.; Goodin, D.; Hartung, H.P.; Jeffery, D.; Kappos, L.; Boateng, F., et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol. 2009, 8, 889-897.
-
(2009)
Lancet Neurol
, vol.8
, pp. 889-897
-
-
O'Connor, P.1
Filippi, M.2
Arnason, B.3
Comi, G.4
Cook, S.5
Goodin, D.6
Hartung, H.P.7
Jeffery, D.8
Kappos, L.9
Boateng, F.10
-
139
-
-
79958007082
-
Recent insights into the mechanism of action of glatiramer acetate
-
Kala, M.; Miravalle, A.; Vollmer, T. Recent insights into the mechanism of action of glatiramer acetate. J. Neuroimmunol. 2011, 235, 9-17.
-
(2011)
J. Neuroimmunol
, vol.235
, pp. 9-17
-
-
Kala, M.1
Miravalle, A.2
Vollmer, T.3
-
140
-
-
0037406714
-
Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells
-
Vieira, P.L.; Heystek, H.C.; Wormmeester, J.; Wierenga, E.A.; Kapsenberg, M.L. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol. 2003, 170, 4483-4488.
-
(2003)
J. Immunol
, vol.170
, pp. 4483-4488
-
-
Vieira, P.L.1
Heystek, H.C.2
Wormmeester, J.3
Wierenga, E.A.4
Kapsenberg, M.L.5
-
141
-
-
77955658134
-
Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE
-
Aharoni, R.; Eilam, R.; Stock, A.; Vainshtein, A.; Shezen, E.; Gal, H.; Friedman, N.; Arnon, R. Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J. Neuroimmunol. 2010, 225, 100-111.
-
(2010)
J. Neuroimmunol
, vol.225
, pp. 100-111
-
-
Aharoni, R.1
Eilam, R.2
Stock, A.3
Vainshtein, A.4
Shezen, E.5
Gal, H.6
Friedman, N.7
Arnon, R.8
-
142
-
-
33645220235
-
Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
-
Jee, Y.; Liu, R.; Bai, X.F.; Campagnolo, D.I.; Shi, F.D.; Vollmer, T.L. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? Int. Immunol. 2006, 18, 537-544.
-
(2006)
Int. Immunol
, vol.18
, pp. 537-544
-
-
Jee, Y.1
Liu, R.2
Bai, X.F.3
Campagnolo, D.I.4
Shi, F.D.5
Vollmer, T.L.6
-
143
-
-
33646879037
-
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis
-
Tennakoon, D.K.; Mehta, R.S.; Ortega, S.B.; Bhoj, V.; Racke, M.K.; Karandikar, N.J. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J. Immunol. 2006, 176, 7119-7129.
-
(2006)
J. Immunol
, vol.176
, pp. 7119-7129
-
-
Tennakoon, D.K.1
Mehta, R.S.2
Ortega, S.B.3
Bhoj, V.4
Racke, M.K.5
Karandikar, N.J.6
-
144
-
-
0036195878
-
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis
-
Karandikar, N.J.; Crawford, M.P.; Yan, X.; Ratts, R.B.; Brenchley, J.M.; Ambrozak, D.R.; Lovett-Racke, A.E.; Frohman, E.M.; Stastny, P.; Douek, D.C., et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J. Clin. Invest. 2002, 109, 641-649.
-
(2002)
J. Clin. Invest
, vol.109
, pp. 641-649
-
-
Karandikar, N.J.1
Crawford, M.P.2
Yan, X.3
Ratts, R.B.4
Brenchley, J.M.5
Ambrozak, D.R.6
Lovett-Racke, A.E.7
Frohman, E.M.8
Stastny, P.9
Douek, D.C.10
-
145
-
-
72749096461
-
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis
-
Kala, M.; Rhodes, S.N.; Piao, W.H.; Shi, F.D.; Campagnolo, D.I.; Vollmer, T.L. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp. Neurol. 2010, 221, 136-145.
-
(2010)
Exp. Neurol
, vol.221
, pp. 136-145
-
-
Kala, M.1
Rhodes, S.N.2
Piao, W.H.3
Shi, F.D.4
Campagnolo, D.I.5
Vollmer, T.L.6
-
146
-
-
77249142775
-
Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis
-
Begum-Haque, S.; Sharma, A.; Christy, M.; Lentini, T.; Ochoa-Reparaz, J.; Fayed, I.F.; Mielcarz, D.; Haque, A.; Kasper, L.H. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2010, 219, 47-53.
-
(2010)
J. Neuroimmunol
, vol.219
, pp. 47-53
-
-
Begum-Haque, S.1
Sharma, A.2
Christy, M.3
Lentini, T.4
Ochoa-Reparaz, J.5
Fayed, I.F.6
Mielcarz, D.7
Haque, A.8
Kasper, L.H.9
-
147
-
-
79952280456
-
Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate
-
Begum-Haque, S.; Christy, M.; Ochoa-Reparaz, J.; Nowak, E.C.; Mielcarz, D.; Haque, A.; Kasper, L.H. Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J. Neuroimmunol. 2011, 232, 136-144.
-
(2011)
J. Neuroimmunol
, vol.232
, pp. 136-144
-
-
Begum-Haque, S.1
Christy, M.2
Ochoa-Reparaz, J.3
Nowak, E.C.4
Mielcarz, D.5
Haque, A.6
Kasper, L.H.7
-
148
-
-
79953890862
-
Glatiramer acetate in the treatment of multiple sclerosis: Emerging concepts regarding its mechanism of action
-
Lalive, P.H.; Neuhaus, O.; Benkhoucha, M.; Burger, D.; Hohlfeld, R.; Zamvil, S.S.; Weber, M.S. Glatiramer acetate in the treatment of multiple sclerosis: Emerging concepts regarding its mechanism of action. CNS Drugs 2011, 25, 401-414.
-
(2011)
CNS Drugs
, vol.25
, pp. 401-414
-
-
Lalive, P.H.1
Neuhaus, O.2
Benkhoucha, M.3
Burger, D.4
Hohlfeld, R.5
Zamvil, S.S.6
Weber, M.S.7
-
149
-
-
34547699396
-
Type II monocytes modulate T cell-mediated central nervous system autoimmune disease
-
Weber, M.S.; Prod'homme, T.; Youssef, S.; Dunn, S.E.; Rundle, C.D.; Lee, L.; Patarroyo, J.C.; Stuve, O.; Sobel, R.A.; Steinman, L., et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 2007, 13, 935-943.
-
(2007)
Nat. Med
, vol.13
, pp. 935-943
-
-
Weber, M.S.1
Prod'homme, T.2
Youssef, S.3
Dunn, S.E.4
Rundle, C.D.5
Lee, L.6
Patarroyo, J.C.7
Stuve, O.8
Sobel, R.A.9
Steinman, L.10
-
150
-
-
79961122749
-
Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis
-
Toker, A.; Slaney, C.Y.; Backstrom, B.T.; Harper, J.L. Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 2011, 74, 235-243.
-
(2011)
Scand. J. Immunol
, vol.74
, pp. 235-243
-
-
Toker, A.1
Slaney, C.Y.2
Backstrom, B.T.3
Harper, J.L.4
-
151
-
-
34248177331
-
Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins
-
Sarchielli, P.; Zaffaroni, M.; Floridi, A.; Greco, L.; Candeliere, A.; Mattioni, A.; Tenaglia, S.; di Filippo, M.; Calabresi, P. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult. Scler. 2007, 13, 313-331.
-
(2007)
Mult. Scler
, vol.13
, pp. 313-331
-
-
Sarchielli, P.1
Zaffaroni, M.2
Floridi, A.3
Greco, L.4
Candeliere, A.5
Mattioni, A.6
Tenaglia, S.7
di Filippo, M.8
Calabresi, P.9
-
152
-
-
33748631025
-
Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: A longitudinal study
-
Blanco, Y.; Moral, E.A.; Costa, M.; Gomez-Choco, M.; Torres-Peraza, J.F.; Alonso-Magdalena, L.; Alberch, J.; Jaraquemada, D.; Arbizu, T.; Graus, F., et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: A longitudinal study. Neurosci. Lett. 2006, 406, 270-275.
-
(2006)
Neurosci. Lett
, vol.406
, pp. 270-275
-
-
Blanco, Y.1
Moral, E.A.2
Costa, M.3
Gomez-Choco, M.4
Torres-Peraza, J.F.5
Alonso-Magdalena, L.6
Alberch, J.7
Jaraquemada, D.8
Arbizu, T.9
Graus, F.10
-
153
-
-
30044451754
-
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice
-
Aharoni, R.; Eilam, R.; Domev, H.; Labunskay, G.; Sela, M.; Arnon, R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. USA 2005, 102, 19045-19050.
-
(2005)
Proc. Natl. Acad. Sci. USA
, vol.102
, pp. 19045-19050
-
-
Aharoni, R.1
Eilam, R.2
Domev, H.3
Labunskay, G.4
Sela, M.5
Arnon, R.6
-
154
-
-
24144469398
-
Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate
-
Azoulay, D.; Vachapova, V.; Shihman, B.; Miler, A.; Karni, A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate. J. Neuroimmunol. 2005, 167, 215-218.
-
(2005)
J. Neuroimmunol
, vol.167
, pp. 215-218
-
-
Azoulay, D.1
Vachapova, V.2
Shihman, B.3
Miler, A.4
Karni, A.5
-
155
-
-
20444414520
-
Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy
-
Ziemssen, T.; Kumpfel, T.; Schneider, H.; Klinkert, W.E.; Neuhaus, O.; Hohlfeld, R. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. J. Neurol. Sci. 2005, 233, 109-112.
-
(2005)
J. Neurol. Sci
, vol.233
, pp. 109-112
-
-
Ziemssen, T.1
Kumpfel, T.2
Schneider, H.3
Klinkert, W.E.4
Neuhaus, O.5
Hohlfeld, R.6
-
156
-
-
84891715600
-
Natalizumab for relapsing remitting multiple sclerosis
-
Pucci, E.; Giuliani, G.; Solari, A.; Simi, S.; Minozzi, S.; di Pietrantonj, C.; Galea, I. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst. Rev. 2011, CD007621.
-
(2011)
Cochrane Database Syst. Rev
-
-
Pucci, E.1
Giuliani, G.2
Solari, A.3
Simi, S.4
Minozzi, S.5
di Pietrantonj, C.6
Galea, I.7
-
157
-
-
84861022041
-
Risk of natalizumab-associated progressive multifocal leukoencephalopathy
-
Bloomgren, G.; Richman, S.; Hotermans, C.; Subramanyam, M.; Goelz, S.; Natarajan, A.; Lee, S.; Plavina, T.; Scanlon, J.V.; Sandrock, A., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2012, 366, 1870-1880.
-
(2012)
N. Engl. J. Med
, vol.366
, pp. 1870-1880
-
-
Bloomgren, G.1
Richman, S.2
Hotermans, C.3
Subramanyam, M.4
Goelz, S.5
Natarajan, A.6
Lee, S.7
Plavina, T.8
Scanlon, J.V.9
Sandrock, A.10
-
158
-
-
84867779332
-
-
Biogen Idec Tysabri Safety Update. Available online, accessed on 23 August 2012
-
Biogen Idec Tysabri Safety Update. Available online: http://www.tapp.com.au/members/Tysabri_Safety_Update_160812.pdf (accessed on 23 August 2012).
-
-
-
-
159
-
-
0015521499
-
Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy
-
Weiner, L.P.; Herndon, R.M.; Narayan, O.; Johnson, R.T.; Shah, K.; Rubinstein, L.J.; Preziosi, T.J.; Conley, F.K. Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. N. Engl. J. Med. 1972, 286, 385-390.
-
(1972)
N. Engl. J. Med
, vol.286
, pp. 385-390
-
-
Weiner, L.P.1
Herndon, R.M.2
Narayan, O.3
Johnson, R.T.4
Shah, K.5
Rubinstein, L.J.6
Preziosi, T.J.7
Conley, F.K.8
-
160
-
-
0029068057
-
Progressive multifocal leukoencephalopathy: Clinical and laboratory observations on a viral induced demyelinating disease in the immunodeficient patient
-
Major, E.O.; Ault, G.S. Progressive multifocal leukoencephalopathy: Clinical and laboratory observations on a viral induced demyelinating disease in the immunodeficient patient. Curr. Opin. Neurol. 1995, 8, 184-190.
-
(1995)
Curr. Opin. Neurol
, vol.8
, pp. 184-190
-
-
Major, E.O.1
Ault, G.S.2
-
161
-
-
79960344014
-
Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring
-
Kappos, L.; Bates, D.; Edan, G.; Eraksoy, M.; Garcia-Merino, A.; Grigoriadis, N.; Hartung, H.P.; Havrdova, E.; Hillert, J.; Hohlfeld, R., et al. Natalizumab treatment for multiple sclerosis: Updated recommendations for patient selection and monitoring. Lancet Neurol. 2011, 10, 745-758.
-
(2011)
Lancet Neurol
, vol.10
, pp. 745-758
-
-
Kappos, L.1
Bates, D.2
Edan, G.3
Eraksoy, M.4
Garcia-Merino, A.5
Grigoriadis, N.6
Hartung, H.P.7
Havrdova, E.8
Hillert, J.9
Hohlfeld, R.10
-
162
-
-
41549130359
-
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients
-
Vellinga, M.M.; Castelijns, J.A.; Barkhof, F.; Uitdehaag, B.M.; Polman, C.H. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008, 70, 1150-1151.
-
(2008)
Neurology
, vol.70
, pp. 1150-1151
-
-
Vellinga, M.M.1
Castelijns, J.A.2
Barkhof, F.3
Uitdehaag, B.M.4
Polman, C.H.5
-
163
-
-
61549088471
-
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
-
Stuve, O.; Cravens, P.D.; Frohman, E.M.; Phillips, J.T.; Remington, G.M.; von Geldern, G.; Cepok, S.; Singh, M.P.; Tervaert, J.W.; de Baets, M., et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009, 72, 396-401.
-
(2009)
Neurology
, vol.72
, pp. 396-401
-
-
Stuve, O.1
Cravens, P.D.2
Frohman, E.M.3
Phillips, J.T.4
Remington, G.M.5
von Geldern, G.6
Cepok, S.7
Singh, M.P.8
Tervaert, J.W.9
de Baets, M.10
-
164
-
-
17644398787
-
Anti-alpha4 integrin therapy for multiple sclerosis: Mechanisms and rationale
-
Rice, G.P.; Hartung, H.P.; Calabresi, P.A. Anti-alpha4 integrin therapy for multiple sclerosis: Mechanisms and rationale. Neurology 2005, 64, 1336-1342.
-
(2005)
Neurology
, vol.64
, pp. 1336-1342
-
-
Rice, G.P.1
Hartung, H.P.2
Calabresi, P.A.3
-
165
-
-
0029076191
-
Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4
-
Sato, T.; Tachibana, K.; Nojima, Y.; D'Avirro, N.; Morimoto, C. Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4. J. Immunol. 1995, 155, 2938-2947.
-
(1995)
J. Immunol
, vol.155
, pp. 2938-2947
-
-
Sato, T.1
Tachibana, K.2
Nojima, Y.3
D'avirro, N.4
Morimoto, C.5
-
166
-
-
80555150830
-
Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism
-
Ramos-Cejudo, J.; Oreja-Guevara, C.; Stark Aroeira, L.; Rodriguez de Antonio, L.; Chamorro, B.; Diez-Tejedor, E. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. J. Clin. Immunol. 2011, 31, 623-631.
-
(2011)
J. Clin. Immunol
, vol.31
, pp. 623-631
-
-
Ramos-Cejudo, J.1
Oreja-Guevara, C.2
Stark, A.L.3
de Antonio, L.G.4
Chamorro, B.5
Diez-Tejedor, E.6
-
167
-
-
79957973246
-
Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients
-
Skarica, M.; Eckstein, C.; Whartenby, K.A.; Calabresi, P.A. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J. Neuroimmunol. 2011, 235, 70-76.
-
(2011)
J. Neuroimmunol
, vol.235
, pp. 70-76
-
-
Skarica, M.1
Eckstein, C.2
Whartenby, K.A.3
Calabresi, P.A.4
-
168
-
-
67650032747
-
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
-
Kivisakk, P.; Healy, B.C.; Viglietta, V.; Quintana, F.J.; Hootstein, M.A.; Weiner, H.L.; Khoury, S.J. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009, 72, 1922-1930.
-
(2009)
Neurology
, vol.72
, pp. 1922-1930
-
-
Kivisakk, P.1
Healy, B.C.2
Viglietta, V.3
Quintana, F.J.4
Hootstein, M.A.5
Weiner, H.L.6
Khoury, S.J.7
-
169
-
-
0344443218
-
Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis
-
Bar-Or, A.; Nuttall, R.K.; Duddy, M.; Alter, A.; Kim, H.J.; Ifergan, I.; Pennington, C.J.; Bourgoin, P.; Edwards, D.R.; Yong, V.W. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003, 126, 2738-2749.
-
(2003)
Brain
, vol.126
, pp. 2738-2749
-
-
Bar-Or, A.1
Nuttall, R.K.2
Duddy, M.3
Alter, A.4
Kim, H.J.5
Ifergan, I.6
Pennington, C.J.7
Bourgoin, P.8
Edwards, D.R.9
Yong, V.W.10
-
170
-
-
84555197737
-
A mechanistically novel, first oral therapy for multiple sclerosis: The development of fingolimod (FTY720, Gilenya)
-
Chun, J.; Brinkmann, V. A mechanistically novel, first oral therapy for multiple sclerosis: The development of fingolimod (FTY720, Gilenya). Discov. Med. 2011, 12, 213-228.
-
(2011)
Discov. Med
, vol.12
, pp. 213-228
-
-
Chun, J.1
Brinkmann, V.2
-
171
-
-
0037379202
-
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment
-
Fujino, M.; Funeshima, N.; Kitazawa, Y.; Kimura, H.; Amemiya, H.; Suzuki, S.; Li, X.K. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 2003, 305, 70-77.
-
(2003)
J. Pharmacol. Exp. Ther
, vol.305
, pp. 70-77
-
-
Fujino, M.1
Funeshima, N.2
Kitazawa, Y.3
Kimura, H.4
Amemiya, H.5
Suzuki, S.6
Li, X.K.7
-
172
-
-
33645283403
-
FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration
-
Kataoka, H.; Sugahara, K.; Shimano, K.; Teshima, K.; Koyama, M.; Fukunari, A.; Chiba, K. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell. Mol. Immunol. 2005, 2, 439-448.
-
(2005)
Cell. Mol. Immunol
, vol.2
, pp. 439-448
-
-
Kataoka, H.1
Sugahara, K.2
Shimano, K.3
Teshima, K.4
Koyama, M.5
Fukunari, A.6
Chiba, K.7
-
173
-
-
3242683494
-
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice
-
Webb, M.; Tham, C.S.; Lin, F.F.; Lariosa-Willingham, K.; Yu, N.; Hale, J.; Mandala, S.; Chun, J.; Rao, T.S. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 2004, 153, 108-121.
-
(2004)
J. Neuroimmunol
, vol.153
, pp. 108-121
-
-
Webb, M.1
Tham, C.S.2
Lin, F.F.3
Lariosa-Willingham, K.4
Yu, N.5
Hale, J.6
Mandala, S.7
Chun, J.8
Rao, T.S.9
-
174
-
-
79955455801
-
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
-
Cohen, J.A.; Chun, J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 2011, 69, 759-777.
-
(2011)
Ann. Neurol
, vol.69
, pp. 759-777
-
-
Cohen, J.A.1
Chun, J.2
-
175
-
-
77955358808
-
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
-
Mehling, M.; Lindberg, R.; Raulf, F.; Kuhle, J.; Hess, C.; Kappos, L.; Brinkmann, V. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010, 75, 403-410.
-
(2010)
Neurology
, vol.75
, pp. 403-410
-
-
Mehling, M.1
Lindberg, R.2
Raulf, F.3
Kuhle, J.4
Hess, C.5
Kappos, L.6
Brinkmann, V.7
-
176
-
-
11144357340
-
Expression of CCR7 in multiple sclerosis: Implications for CNS immunity
-
Kivisakk, P.; Mahad, D.J.; Callahan, M.K.; Sikora, K.; Trebst, C.; Tucky, B.; Wujek, J.; Ravid, R.; Staugaitis, S.M.; Lassmann, H., et al. Expression of CCR7 in multiple sclerosis: Implications for CNS immunity. Ann. Neurol. 2004, 55, 627-638.
-
(2004)
Ann. Neurol
, vol.55
, pp. 627-638
-
-
Kivisakk, P.1
Mahad, D.J.2
Callahan, M.K.3
Sikora, K.4
Trebst, C.5
Tucky, B.6
Wujek, J.7
Ravid, R.8
Staugaitis, S.M.9
Lassmann, H.10
-
177
-
-
79551674537
-
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation
-
Choi, J.W.; Gardell, S.E.; Herr, D.R.; Rivera, R.; Lee, C.W.; Noguchi, K.; Teo, S.T.; Yung, Y.C.; Lu, M.; Kennedy, G., et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl. Acad. Sci. USA 2011, 108, 751-756.
-
(2011)
Proc. Natl. Acad. Sci. USA
, vol.108
, pp. 751-756
-
-
Choi, J.W.1
Gardell, S.E.2
Herr, D.R.3
Rivera, R.4
Lee, C.W.5
Noguchi, K.6
Teo, S.T.7
Yung, Y.C.8
Lu, M.9
Kennedy, G.10
-
178
-
-
20244383720
-
Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients
-
Altmeyer, P.J.; Matthes, U.; Pawlak, F.; Hoffmann, K.; Frosch, P.J.; Ruppert, P.; Wassilew, S.W.; Horn, T.; Kreysel, H.W.; Lutz, G., et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J. Am. Acad. Dermarol. 1994, 30, 977-981.
-
(1994)
J. Am. Acad. Dermarol
, vol.30
, pp. 977-981
-
-
Altmeyer, P.J.1
Matthes, U.2
Pawlak, F.3
Hoffmann, K.4
Frosch, P.J.5
Ruppert, P.6
Wassilew, S.W.7
Horn, T.8
Kreysel, H.W.9
Lutz, G.10
-
179
-
-
65949111054
-
Fumaric Acid and its esters: An emerging treatment for multiple sclerosis
-
Moharregh-Khiabani, D.; Linker, R.A.; Gold, R.; Stangel, M. Fumaric Acid and its esters: An emerging treatment for multiple sclerosis. Curr. Neuropharmacol. 2009, 7, 60-64.
-
(2009)
Curr. Neuropharmacol
, vol.7
, pp. 60-64
-
-
Moharregh-Khiabani, D.1
Linker, R.A.2
Gold, R.3
Stangel, M.4
-
180
-
-
84856641109
-
NF-kappaB, the first quarter-century: Remarkable progress and outstanding questions
-
Hayden, M.S.; Ghosh, S. NF-kappaB, the first quarter-century: Remarkable progress and outstanding questions. Genes Dev. 2012, 26, 203-234.
-
(2012)
Genes Dev
, vol.26
, pp. 203-234
-
-
Hayden, M.S.1
Ghosh, S.2
-
182
-
-
0029846154
-
Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate
-
de Jong, R.; Bezemer, A.C.; Zomerdijk, T.P.; van de Pouw-Kraan, T.; Ottenhoff, T.H.; Nibbering, P.H. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol. 1996, 26, 2067-2074.
-
(1996)
Eur. J. Immunol
, vol.26
, pp. 2067-2074
-
-
de Jong, R.1
Bezemer, A.C.2
Zomerdijk, T.P.3
van de Pouw-Kraan, T.4
Ottenhoff, T.H.5
Nibbering, P.H.6
-
183
-
-
0345732760
-
Dimethylfumarate is a potent inducer of apoptosis in human T cells
-
Treumer, F.; Zhu, K.; Glaser, R.; Mrowietz, U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J. Invest. Dermatol. 2003, 121, 1383-1388.
-
(2003)
J. Invest. Dermatol
, vol.121
, pp. 1383-1388
-
-
Treumer, F.1
Zhu, K.2
Glaser, R.3
Mrowietz, U.4
-
184
-
-
33745162188
-
Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration
-
Schilling, S.; Goelz, S.; Linker, R.; Luehder, F.; Gold, R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 2006, 145, 101-107.
-
(2006)
Clin. Exp. Immunol
, vol.145
, pp. 101-107
-
-
Schilling, S.1
Goelz, S.2
Linker, R.3
Luehder, F.4
Gold, R.5
-
185
-
-
79952136166
-
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
-
Linker, R.A.; Lee, D.H.; Ryan, S.; van Dam, A.M.; Conrad, R.; Bista, P.; Zeng, W.; Hronowsky, X.; Buko, A.; Chollate, S., et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134, 678-692.
-
(2011)
Brain
, vol.134
, pp. 678-692
-
-
Linker, R.A.1
Lee, D.H.2
Ryan, S.3
van Dam, A.M.4
Conrad, R.5
Bista, P.6
Zeng, W.7
Hronowsky, X.8
Buko, A.9
Chollate, S.10
-
186
-
-
84858648216
-
Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway
-
Scannevin, R.H.; Chollate, S.; Jung, M.Y.; Shackett, M.; Patel, H.; Bista, P.; Zeng, W.; Ryan, S.; Yamamoto, M.; Lukashev, M., et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J. Pharmacol. Exp. Ther. 2012, 341, 274-284.
-
(2012)
J. Pharmacol. Exp. Ther
, vol.341
, pp. 274-284
-
-
Scannevin, R.H.1
Chollate, S.2
Jung, M.Y.3
Shackett, M.4
Patel, H.5
Bista, P.6
Zeng, W.7
Ryan, S.8
Yamamoto, M.9
Lukashev, M.10
-
187
-
-
79958153194
-
The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1
-
doi:10.1042/AN20100033
-
Lin, S.X.; Lisi, L.; Dello Russo, C.; Polak, P.E.; Sharp, A.; Weinberg, G.; Kalinin, S.; Feinstein, D.L. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 2011, 3, doi:10.1042/AN20100033.
-
(2011)
ASN Neuro
, vol.3
-
-
Lin, S.X.1
Lisi, L.2
Dello, R.C.3
Polak, P.E.4
Sharp, A.5
Weinberg, G.6
Kalinin, S.7
Feinstein, D.L.8
-
188
-
-
70449253356
-
Treatment of psoriasis vulgaris
-
Schweckendiek, W. Treatment of psoriasis vulgaris. Med. Monatsschr. 1959, 13, 103-104.
-
(1959)
Med. Monatsschr
, vol.13
, pp. 103-104
-
-
Schweckendiek, W.1
-
189
-
-
84856220315
-
Immune mechanisms of new therapeutic strategies in MS: Teriflunomide
-
Claussen, M.C.; Korn, T. Immune mechanisms of new therapeutic strategies in MS: Teriflunomide. Clin. Immunol. 2012, 142, 49-56.
-
(2012)
Clin. Immunol
, vol.142
, pp. 49-56
-
-
Claussen, M.C.1
Korn, T.2
-
190
-
-
0037105395
-
Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation
-
Dimitrova, P.; Skapenko, A.; Herrmann, M.L.; Schleyerbach, R.; Kalden, J.R.; Schulze-Koops, H. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J. Immunol. 2002, 169, 3392-3399.
-
(2002)
J. Immunol
, vol.169
, pp. 3392-3399
-
-
Dimitrova, P.1
Skapenko, A.2
Herrmann, M.L.3
Schleyerbach, R.4
Kalden, J.R.5
Schulze-Koops, H.6
-
191
-
-
0029052321
-
Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide
-
Xu, X.; Williams, J.W.; Bremer, E.G.; Finnegan, A.; Chong, A.S. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J. Biol. Chem. 1995, 270, 12398-12403.
-
(1995)
J. Biol. Chem
, vol.270
, pp. 12398-12403
-
-
Xu, X.1
Williams, J.W.2
Bremer, E.G.3
Finnegan, A.4
Chong, A.S.5
-
192
-
-
25444448197
-
Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation
-
Zeyda, M.; Poglitsch, M.; Geyeregger, R.; Smolen, J.S.; Zlabinger, G.J.; Horl, W.H.; Waldhausl, W.; Stulnig, T.M.; Saemann, M.D. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 2005, 52, 2730-2739.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 2730-2739
-
-
Zeyda, M.1
Poglitsch, M.2
Geyeregger, R.3
Smolen, J.S.4
Zlabinger, G.J.5
Horl, W.H.6
Waldhausl, W.7
Stulnig, T.M.8
Saemann, M.D.9
-
193
-
-
7644223637
-
Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-Mechanisms independent of pyrimidine depletion
-
Korn, T.; Magnus, T.; Toyka, K.; Jung, S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-Mechanisms independent of pyrimidine depletion. J. Leukoc. Biol. 2004, 76, 950-960.
-
(2004)
J. Leukoc. Biol
, vol.76
, pp. 950-960
-
-
Korn, T.1
Magnus, T.2
Toyka, K.3
Jung, S.4
-
194
-
-
62149096116
-
Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis
-
Merrill, J.E.; Hanak, S.; Pu, S.F.; Liang, J.; Dang, C.; Iglesias-Bregna, D.; Harvey, B.; Zhu, B.; McMonagle-Strucko, K. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J. Neurol. 2009, 256, 89-103.
-
(2009)
J. Neurol
, vol.256
, pp. 89-103
-
-
Merrill, J.E.1
Hanak, S.2
Pu, S.F.3
Liang, J.4
Dang, C.5
Iglesias-Bregna, D.6
Harvey, B.7
Zhu, B.8
McMonagle-Strucko, K.9
-
195
-
-
0034624943
-
North American Linomide Investigators. Linomide in relapsing and secondary progressive MS: Part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the
-
Wolinsky, J.S.; Narayana, P.A.; Noseworthy, J.H.; Lublin, F.D.; Whitaker, J.N.; Linde, A.; Gjorstrup, P.; Sullivan, H.C.; North American Linomide Investigators. Linomide in relapsing and secondary progressive MS: Part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the. Neurology 2000, 54, 1734-1741.
-
(2000)
Neurology
, vol.54
, pp. 1734-1741
-
-
Wolinsky, J.S.1
Narayana, P.A.2
Noseworthy, J.H.3
Lublin, F.D.4
Whitaker, J.N.5
Linde, A.6
Gjorstrup, P.7
Sullivan, H.C.8
-
196
-
-
0034624942
-
North American Linomide Investigators. Linomide in relapsing and secondary progressive MS: Part I: Trial design and clinical results
-
Noseworthy, J.H.; Wolinsky, J.S.; Lublin, F.D.; Whitaker, J.N.; Linde, A.; Gjorstrup, P.; Sullivan, H.C. North American Linomide Investigators. Linomide in relapsing and secondary progressive MS: Part I: Trial design and clinical results. Neurology 2000, 54, 1726-1733.
-
(2000)
Neurology
, vol.54
, pp. 1726-1733
-
-
Noseworthy, J.H.1
Wolinsky, J.S.2
Lublin, F.D.3
Whitaker, J.N.4
Linde, A.5
Gjorstrup, P.6
Sullivan, H.C.7
-
197
-
-
0034003613
-
Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials
-
Tan, I.L.; Nijeholt, G.J.L.; Polman, C.H.; Ader, H.J.; Barkhof, F. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Mult. Scler. 2000, 6, 99-104.
-
(2000)
Mult. Scler
, vol.6
, pp. 99-104
-
-
Tan, I.L.1
Nijeholt, G.J.L.2
Polman, C.H.3
Ader, H.J.4
Barkhof, F.5
-
198
-
-
77956649428
-
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis
-
Wegner, C.; Stadelmann, C.; Pfortner, R.; Raymond, E.; Feigelson, S.; Alon, R.; Timan, B.; Hayardeny, L.; Bruck, W. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2010, 227, 133-143.
-
(2010)
J. Neuroimmunol
, vol.227
, pp. 133-143
-
-
Wegner, C.1
Stadelmann, C.2
Pfortner, R.3
Raymond, E.4
Feigelson, S.5
Alon, R.6
Timan, B.7
Hayardeny, L.8
Bruck, W.9
-
199
-
-
0036710356
-
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis
-
Brunmark, C.; Runstrom, A.; Ohlsson, L.; Sparre, B.; Brodin, T.; Astrom, M.; Hedlund, G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002, 130, 163-172.
-
(2002)
J. Neuroimmunol
, vol.130
, pp. 163-172
-
-
Brunmark, C.1
Runstrom, A.2
Ohlsson, L.3
Sparre, B.4
Brodin, T.5
Astrom, M.6
Hedlund, G.7
-
200
-
-
4744340401
-
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats
-
Yang, J.S.; Xu, L.Y.; Xiao, B.G.; Hedlund, G.; Link, H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 2004, 156, 3-9.
-
(2004)
J. Neuroimmunol
, vol.156
, pp. 3-9
-
-
Yang, J.S.1
Xu, L.Y.2
Xiao, B.G.3
Hedlund, G.4
Link, H.5
-
201
-
-
79958770585
-
Insight into the mechanism of laquinimod action
-
Bruck, W.; Wegner, C. Insight into the mechanism of laquinimod action. J. Neurol. Sci. 2011, 306, 173-179.
-
(2011)
J. Neurol. Sci
, vol.306
, pp. 173-179
-
-
Bruck, W.1
Wegner, C.2
-
202
-
-
0036240732
-
Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue
-
Zou, L.P.; Abbas, N.; Volkmann, I.; Nennesmo, I.; Levi, M.; Wahren, B.; Winblad, B.; Hedlund, G.; Zhu, J. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002, 42, 731-739.
-
(2002)
Neuropharmacology
, vol.42
, pp. 731-739
-
-
Zou, L.P.1
Abbas, N.2
Volkmann, I.3
Nennesmo, I.4
Levi, M.5
Wahren, B.6
Winblad, B.7
Hedlund, G.8
Zhu, J.9
-
203
-
-
77951218761
-
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In-vitro high-throughput gene expression study
-
Gurevich, M.; Gritzman, T.; Orbach, R.; Tuller, T.; Feldman, A.; Achiron, A. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In-vitro high-throughput gene expression study. J. Neuroimmunol. 2010, 221, 87-94.
-
(2010)
J. Neuroimmunol
, vol.221
, pp. 87-94
-
-
Gurevich, M.1
Gritzman, T.2
Orbach, R.3
Tuller, T.4
Feldman, A.5
Achiron, A.6
-
204
-
-
83555174399
-
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor
-
Thone, J.; Ellrichmann, G.; Seubert, S.; Peruga, I.; Lee, D.H.; Conrad, R.; Hayardeny, L.; Comi, G.; Wiese, S.; Linker, R.A., et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am. J. Pathol. 2012, 180, 267-274.
-
(2012)
Am. J. Pathol
, vol.180
, pp. 267-274
-
-
Thone, J.1
Ellrichmann, G.2
Seubert, S.3
Peruga, I.4
Lee, D.H.5
Conrad, R.6
Hayardeny, L.7
Comi, G.8
Wiese, S.9
Linker, R.A.10
-
205
-
-
77957062260
-
Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: Therapeutic implications in a model of multiple sclerosis
-
Linker, R.A.; Lee, D.H.; Demir, S.; Wiese, S.; Kruse, N.; Siglienti, I.; Gerhardt, E.; Neumann, H.; Sendtner, M.; Luhder, F., et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: Therapeutic implications in a model of multiple sclerosis. Brain 2010, 133, 2248-2263.
-
(2010)
Brain
, vol.133
, pp. 2248-2263
-
-
Linker, R.A.1
Lee, D.H.2
Demir, S.3
Wiese, S.4
Kruse, N.5
Siglienti, I.6
Gerhardt, E.7
Neumann, H.8
Sendtner, M.9
Luhder, F.10
-
206
-
-
84857030341
-
Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination
-
Lee, D.H.; Geyer, E.; Flach, A.C.; Jung, K.; Gold, R.; Flugel, A.; Linker, R.A.; Luhder, F. Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol. 2012, 123, 247-258.
-
(2012)
Acta Neuropathol
, vol.123
, pp. 247-258
-
-
Lee, D.H.1
Geyer, E.2
Flach, A.C.3
Jung, K.4
Gold, R.5
Flugel, A.6
Linker, R.A.7
Luhder, F.8
-
207
-
-
0027240401
-
Effect of Campath-1H antibody on human hematopoietic progenitors in vitro
-
Gilleece, M.H.; Dexter, T.M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993, 82, 807-812.
-
(1993)
Blood
, vol.82
, pp. 807-812
-
-
Gilleece, M.H.1
Dexter, T.M.2
-
208
-
-
84860780657
-
Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial
-
Coles, A.J.; Fox, E.; Vladic, A.; Gazda, S.K.; Brinar, V.; Selmaj, K.W.; Skoromets, A.; Stolyarov, I.; Bass, A.; Sullivan, H., et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012, 78, 1069-1078.
-
(2012)
Neurology
, vol.78
, pp. 1069-1078
-
-
Coles, A.J.1
Fox, E.2
Vladic, A.3
Gazda, S.K.4
Brinar, V.5
Selmaj, K.W.6
Skoromets, A.7
Stolyarov, I.8
Bass, A.9
Sullivan, H.10
-
209
-
-
31544467633
-
The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy
-
Coles, A.J.; Cox, A.; Le Page, E.; Jones, J.; Trip, S.A.; Deans, J.; Seaman, S.; Miller, D.H.; Hale, G.; Waldmann, H., et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J. Neurol. 2006, 253, 98-108.
-
(2006)
J. Neurol
, vol.253
, pp. 98-108
-
-
Coles, A.J.1
Cox, A.2
Le Page, E.3
Jones, J.4
Trip, S.A.5
Deans, J.6
Seaman, S.7
Miller, D.H.8
Hale, G.9
Waldmann, H.10
-
210
-
-
77249114139
-
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis
-
Thompson, S.A.; Jones, J.L.; Cox, A.L.; Compston, D.A.; Coles, A.J. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol. 2010, 30, 99-105.
-
(2010)
J. Clin. Immunol
, vol.30
, pp. 99-105
-
-
Thompson, S.A.1
Jones, J.L.2
Cox, A.L.3
Compston, D.A.4
Coles, A.J.5
-
211
-
-
27944439639
-
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
-
Cox, A.L.; Thompson, S.A.; Jones, J.L.; Robertson, V.H.; Hale, G.; Waldmann, H.; Compston, D.A.; Coles, A.J. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 2005, 35, 3332-3342.
-
(2005)
Eur. J. Immunol
, vol.35
, pp. 3332-3342
-
-
Cox, A.L.1
Thompson, S.A.2
Jones, J.L.3
Robertson, V.H.4
Hale, G.5
Waldmann, H.6
Compston, D.A.7
Coles, A.J.8
-
212
-
-
54949143968
-
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
-
Coles, A.J.; Compston, D.A.; Selmaj, K.W.; Lake, S.L.; Moran, S.; Margolin, D.H.; Norris, K.; Tandon, P.K. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 2008, 359, 1786-1801.
-
(2008)
N. Engl. J. Med
, vol.359
, pp. 1786-1801
-
-
Coles, A.J.1
Compston, D.A.2
Selmaj, K.W.3
Lake, S.L.4
Moran, S.5
Margolin, D.H.6
Norris, K.7
Tandon, P.K.8
-
213
-
-
68849084141
-
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
-
Jones, J.L.; Phuah, C.L.; Cox, A.L.; Thompson, S.A.; Ban, M.; Shawcross, J.; Walton, A.; Sawcer, S.J.; Compston, A.; Coles, A.J. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 2009, 119, 2052-2061.
-
(2009)
J. Clin. Invest
, vol.119
, pp. 2052-2061
-
-
Jones, J.L.1
Phuah, C.L.2
Cox, A.L.3
Thompson, S.A.4
Ban, M.5
Shawcross, J.6
Walton, A.7
Sawcer, S.J.8
Compston, A.9
Coles, A.J.10
-
214
-
-
43249103954
-
Getting specific: Monoclonal antibodies in multiple sclerosis
-
Lutterotti, A.; Martin, R. Getting specific: Monoclonal antibodies in multiple sclerosis. Lancet Neurol. 2008, 7, 538-547.
-
(2008)
Lancet Neurol
, vol.7
, pp. 538-547
-
-
Lutterotti, A.1
Martin, R.2
-
215
-
-
33750219508
-
Both integrated and differential regulation of components of the IL-2/IL-2 receptor system
-
Kim, H.P.; Imbert, J.; Leonard, W.J. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 2006, 17, 349-366.
-
(2006)
Cytokine Growth Factor Rev
, vol.17
, pp. 349-366
-
-
Kim, H.P.1
Imbert, J.2
Leonard, W.J.3
-
216
-
-
70350571663
-
High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis
-
Sen, H.N.; Levy-Clarke, G.; Faia, L.J.; Li, Z.; Yeh, S.; Barron, K.S.; Ryan, J.G.; Hammel, K.; Nussenblatt, R.B. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am. J. Ophthalmol.2009, 148, 696-703 e691.
-
(2009)
Am. J. Ophthalmol
, vol.148
-
-
Sen, H.N.1
Levy-Clarke, G.2
Faia, L.J.3
Li, Z.4
Yeh, S.5
Barron, K.S.6
Ryan, J.G.7
Hammel, K.8
Nussenblatt, R.B.9
-
217
-
-
50549090768
-
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis
-
Yeh, S.; Wroblewski, K.; Buggage, R.; Li, Z.; Kurup, S.K.; Sen, H.N.; Dahr, S.; Sran, P.; Reed, G.F.; Robinson, R., et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J. Autoimmun. 2008, 31, 91-97.
-
(2008)
J. Autoimmun
, vol.31
, pp. 91-97
-
-
Yeh, S.1
Wroblewski, K.2
Buggage, R.3
Li, Z.4
Kurup, S.K.5
Sen, H.N.6
Dahr, S.7
Sran, P.8
Reed, G.F.9
Robinson, R.10
-
218
-
-
34250177933
-
A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease
-
Buggage, R.R.; Levy-Clarke, G.; Sen, H.N.; Ursea, R.; Srivastava, S.K.; Suhler, E.B.; Altemare, C.; Velez, G.; Ragheb, J.; Chan, C.C., et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul. Immunol. Inflamm. 2007, 15, 63-70.
-
(2007)
Ocul. Immunol. Inflamm
, vol.15
, pp. 63-70
-
-
Buggage, R.R.1
Levy-Clarke, G.2
Sen, H.N.3
Ursea, R.4
Srivastava, S.K.5
Suhler, E.B.6
Altemare, C.7
Velez, G.8
Ragheb, J.9
Chan, C.C.10
-
219
-
-
13044311376
-
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial
-
Nussenblatt, R.B.; Fortin, E.; Schiffman, R.; Rizzo, L.; Smith, J.; van Veldhuisen, P.; Sran, P.; Yaffe, A.; Goldman, C.K.; Waldmann, T.A., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial. Proc. Natl. Acad. Sci. USA 1999, 96, 7462-7466.
-
(1999)
Proc. Natl. Acad. Sci. USA
, vol.96
, pp. 7462-7466
-
-
Nussenblatt, R.B.1
Fortin, E.2
Schiffman, R.3
Rizzo, L.4
Smith, J.5
van Veldhuisen, P.6
Sran, P.7
Yaffe, A.8
Goldman, C.K.9
Waldmann, T.A.10
-
220
-
-
84921703405
-
Interleukin 2 receptor antagonists for kidney transplant recipients
-
Webster, A.C.; Ruster, L.P.; McGee, R.; Matheson, S.L.; Higgins, G.Y.; Willis, N.S.; Chapman, J.R.; Craig, J.C. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst. Rev. 2010, CD003897.
-
(2010)
Cochrane Database Syst. Rev
-
-
Webster, A.C.1
Ruster, L.P.2
McGee, R.3
Matheson, S.L.4
Higgins, G.Y.5
Willis, N.S.6
Chapman, J.R.7
Craig, J.C.8
-
221
-
-
77949301468
-
Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
-
Wynn, D.; Kaufman, M.; Montalban, X.; Vollmer, T.; Simon, J.; Elkins, J.; O'Neill, G.; Neyer, L.; Sheridan, J.; Wang, C., et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010, 9, 381-390.
-
(2010)
Lancet Neurol
, vol.9
, pp. 381-390
-
-
Wynn, D.1
Kaufman, M.2
Montalban, X.3
Vollmer, T.4
Simon, J.5
Elkins, J.6
O'Neill, G.7
Neyer, L.8
Sheridan, J.9
Wang, C.10
-
222
-
-
84857334054
-
A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relasping-remitting multiple sclerosis: Primary results of the SELECT trial
-
Amsterdam, The Netherlands, 19-22 October
-
Giovannoni, G.; Gold, R.; Selmaj, K.; Havrdova, E.; Montalban, X.; Radue, E.W.; Stefoski, D.; Robinson, R.; Riester, K.; Elkins, J., et al. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relasping-remitting multiple sclerosis: Primary results of the SELECT trial. In Proceedings of European and Americas Committees on Treatment and Research in Multiple Sclerosis (ECTRIMS), Amsterdam, The Netherlands, 19-22 October 2011.
-
(2011)
Proceedings of European and Americas Committees On Treatment and Research In Multiple Sclerosis (ECTRIMS)
-
-
Giovannoni, G.1
Gold, R.2
Selmaj, K.3
Havrdova, E.4
Montalban, X.5
Radue, E.W.6
Stefoski, D.7
Robinson, R.8
Riester, K.9
Elkins, J.10
-
223
-
-
77955506880
-
An IL-2 paradox: Blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells
-
Martin, J.F.; Perry, J.S.; Jakhete, N.R.; Wang, X.; Bielekova, B. An IL-2 paradox: Blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J. Immunol. 2010, 185, 1311-1320.
-
(2010)
J. Immunol
, vol.185
, pp. 1311-1320
-
-
Martin, J.F.1
Perry, J.S.2
Jakhete, N.R.3
Wang, X.4
Bielekova, B.5
-
224
-
-
79955476247
-
Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation
-
Hao, J.; Campagnolo, D.; Liu, R.; Piao, W.; Shi, S.; Hu, B.; Xiang, R.; Zhou, Q.; Vollmer, T.; van Kaer, L.; et al. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann. Neurol. 2011, 69, 721-734.
-
(2011)
Ann. Neurol
, vol.69
, pp. 721-734
-
-
Hao, J.1
Campagnolo, D.2
Liu, R.3
Piao, W.4
Shi, S.5
Hu, B.6
Xiang, R.7
Zhou, Q.8
Vollmer, T.9
van Kaer, L.10
-
225
-
-
65249138318
-
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis
-
Bielekova, B.; Howard, T.; Packer, A.N.; Richert, N.; Blevins, G.; Ohayon, J.; Waldmann, T.A.; McFarland, H.F.; Martin, R. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 2009, 66, 483-489.
-
(2009)
Arch. Neurol
, vol.66
, pp. 483-489
-
-
Bielekova, B.1
Howard, T.2
Packer, A.N.3
Richert, N.4
Blevins, G.5
Ohayon, J.6
Waldmann, T.A.7
McFarland, H.F.8
Martin, R.9
-
226
-
-
0033945954
-
Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy
-
Fehniger, T.A.; Bluman, E.M.; Porter, M.M.; Mrozek, E.; Cooper, M.A.; VanDeusen, J.B.; Frankel, S.R.; Stock, W.; Caligiuri, M.A. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J. Clin. Invest. 2000, 106, 117-124.
-
(2000)
J. Clin. Invest
, vol.106
, pp. 117-124
-
-
Fehniger, T.A.1
Bluman, E.M.2
Porter, M.M.3
Mrozek, E.4
Cooper, M.A.5
Vandeusen, J.B.6
Frankel, S.R.7
Stock, W.8
Caligiuri, M.A.9
-
227
-
-
77956242237
-
Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology
-
Hao, J.; Liu, R.; Piao, W.; Zhou, Q.; Vollmer, T.L.; Campagnolo, D.I.; Xiang, R.; La Cava, A.; van Kaer, L.; Shi, F.D. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 2010, 207, 1907-1921.
-
(2010)
J. Exp. Med
, vol.207
, pp. 1907-1921
-
-
Hao, J.1
Liu, R.2
Piao, W.3
Zhou, Q.4
Vollmer, T.L.5
Campagnolo, D.I.6
Xiang, R.7
la Cava, A.8
van Kaer, L.9
Shi, F.D.10
-
228
-
-
33645812129
-
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis
-
Bielekova, B.; Catalfamo, M.; Reichert-Scrivner, S.; Packer, A.; Cerna, M.; Waldmann, T.A.; McFarland, H.; Henkart, P.A.; Martin, R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA 2006, 103, 5941-5946.
-
(2006)
Proc. Natl. Acad. Sci. USA
, vol.103
, pp. 5941-5946
-
-
Bielekova, B.1
Catalfamo, M.2
Reichert-Scrivner, S.3
Packer, A.4
Cerna, M.5
Waldmann, T.A.6
McFarland, H.7
Henkart, P.A.8
Martin, R.9
-
229
-
-
79955700857
-
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy
-
Wuest, S.C.; Edwan, J.H.; Martin, J.F.; Han, S.; Perry, J.S.; Cartagena, C.M.; Matsuura, E.; Maric, D.; Waldmann, T.A.; Bielekova, B. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 2011, 17, 604-609.
-
(2011)
Nat. Med
, vol.17
, pp. 604-609
-
-
Wuest, S.C.1
Edwan, J.H.2
Martin, J.F.3
Han, S.4
Perry, J.S.5
Cartagena, C.M.6
Matsuura, E.7
Maric, D.8
Waldmann, T.A.9
Bielekova, B.10
-
230
-
-
34250024900
-
Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production
-
Snyder, J.T.; Shen, J.; Azmi, H.; Hou, J.; Fowler, D.H.; Ragheb, J.A. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood 2007, 109, 5399-5406.
-
(2007)
Blood
, vol.109
, pp. 5399-5406
-
-
Snyder, J.T.1
Shen, J.2
Azmi, H.3
Hou, J.4
Fowler, D.H.5
Ragheb, J.A.6
-
231
-
-
84856297433
-
Treatment of multiple sclerosis with anti-CD20 antibodies
-
Barun, B.; Bar-Or, A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol. 2012, 142, 31-37.
-
(2012)
Clin. Immunol
, vol.142
, pp. 31-37
-
-
Barun, B.1
Bar-Or, A.2
-
232
-
-
33646362290
-
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
-
Edwards, J.C.; Cambridge, G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 2006, 6, 394-403.
-
(2006)
Nat. Rev. Immunol
, vol.6
, pp. 394-403
-
-
Edwards, J.C.1
Cambridge, G.2
-
233
-
-
80052777262
-
Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis
-
Clifford, D.B.; Ances, B.; Costello, C.; Rosen-Schmidt, S.; Andersson, M.; Parks, D.; Perry, A.; Yerra, R.; Schmidt, R.; Alvarez, E., et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch. Neurol. 2011, 68, 1156-1164.
-
(2011)
Arch. Neurol
, vol.68
, pp. 1156-1164
-
-
Clifford, D.B.1
Ances, B.2
Costello, C.3
Rosen-Schmidt, S.4
Andersson, M.5
Parks, D.6
Perry, A.7
Yerra, R.8
Schmidt, R.9
Alvarez, E.10
-
234
-
-
84865315420
-
Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies
-
Molloy, E.S.; Calabrese, L.H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies. Arthritis Rheum. 2012, 64, 3043-3051.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 3043-3051
-
-
Molloy, E.S.1
Calabrese, L.H.2
-
235
-
-
77950551323
-
Progressive multifocal leukoencephalopathy: A report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab
-
Tuccori, M.; Focosi, D.; Maggi, F.; Cosottini, M.; Meini, B.; Lena, F.; Blandizzi, C.; del Tacca, M.; Petrini, M. Progressive multifocal leukoencephalopathy: A report of three cases in HIV-negative patients with non-Hodgkin's lymphomas treated with rituximab. Ann. Hematol. 2010, 89, 519-522.
-
(2010)
Ann. Hematol
, vol.89
, pp. 519-522
-
-
Tuccori, M.1
Focosi, D.2
Maggi, F.3
Cosottini, M.4
Meini, B.5
Lena, F.6
Blandizzi, C.7
del Tacca, M.8
Petrini, M.9
-
236
-
-
70449418132
-
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
-
Hawker, K.; O'Connor, P.; Freedman, M.S.; Calabresi, P.A.; Antel, J.; Simon, J.; Hauser, S.; Waubant, E.; Vollmer, T.; Panitch, H., et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009, 66, 460-471.
-
(2009)
Ann. Neurol
, vol.66
, pp. 460-471
-
-
Hawker, K.1
O'Connor, P.2
Freedman, M.S.3
Calabresi, P.A.4
Antel, J.5
Simon, J.6
Hauser, S.7
Waubant, E.8
Vollmer, T.9
Panitch, H.10
-
237
-
-
84897368225
-
Rituximab for relapsing-remitting multiple sclerosis
-
doi:10.1002/14651858.CD009130.pub2
-
He, D.; Zhou, H.; Han, W.; Zhang, S. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst. Rev. 2011, doi:10.1002/14651858.CD009130.pub2.
-
(2011)
Cochrane Database Syst. Rev
-
-
He, D.1
Zhou, H.2
Han, W.3
Zhang, S.4
-
238
-
-
77953341196
-
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis
-
Piccio, L.; Naismith, R.T.; Trinkaus, K.; Klein, R.S.; Parks, B.J.; Lyons, J.A.; Cross, A.H. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 2010, 67, 707-714.
-
(2010)
Arch. Neurol
, vol.67
, pp. 707-714
-
-
Piccio, L.1
Naismith, R.T.2
Trinkaus, K.3
Klein, R.S.4
Parks, B.J.5
Lyons, J.A.6
Cross, A.H.7
-
239
-
-
84863803849
-
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells
-
Barr, T.A.; Shen, P.; Brown, S.; Lampropoulou, V.; Roch, T.; Lawrie, S.; Fan, B.; O'Connor, R.A.; Anderton, S.M.; Bar-Or, A. et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 2012, 209, 1001-1010.
-
(2012)
J. Exp. Med
, vol.209
, pp. 1001-1010
-
-
Barr, T.A.1
Shen, P.2
Brown, S.3
Lampropoulou, V.4
Roch, T.5
Lawrie, S.6
Fan, B.7
O'Connor, R.A.8
Anderton, S.M.9
Bar-Or, A.10
-
240
-
-
51849148443
-
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
-
Genovese, M.C.; Kaine, J.L.; Lowenstein, M.B.; Del Giudice, J.; Baldassare, A.; Schechtman, J.; Fudman, E.; Kohen, M.; Gujrathi, S.; Trapp, R.G., et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008, 58, 2652-2661.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 2652-2661
-
-
Genovese, M.C.1
Kaine, J.L.2
Lowenstein, M.B.3
Del Giudice, J.4
Baldassare, A.5
Schechtman, J.6
Fudman, E.7
Kohen, M.8
Gujrathi, S.9
Trapp, R.G.10
-
241
-
-
81555202418
-
Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial
-
Kappos, L.; Li, D.; Calabresi, P.A.; O'Connor, P.; Bar-Or, A.; Barkhof, F.; Yin, M.; Leppert, D.; Glanzman, R.; Tinbergen, J.; Hauser, S.L. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378, 1779-1787.
-
(2011)
Lancet
, vol.378
, pp. 1779-1787
-
-
Kappos, L.1
Li, D.2
Calabresi, P.A.3
O'Connor, P.4
Bar-Or, A.5
Barkhof, F.6
Yin, M.7
Leppert, D.8
Glanzman, R.9
Tinbergen, J.10
Hauser, S.L.11
-
242
-
-
84863841745
-
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: The phase III FILM trial
-
doi:10.1136/annrheumdis-2011-200706
-
Stohl, W.; Gomez-Reino, J.; Olech, E.; Dudler, J.; Fleischmann, R.M.; Zerbini, C.A.; Ashrafzadeh, A.; Grzeschik, S.; Bieraugel, R.; Green, J.; et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: The phase III FILM trial. Ann. Rheum. Dis. 2012, doi:10.1136/annrheumdis-2011-200706.
-
(2012)
Ann. Rheum. Dis
-
-
Stohl, W.1
Gomez-Reino, J.2
Olech, E.3
Dudler, J.4
Fleischmann, R.M.5
Zerbini, C.A.6
Ashrafzadeh, A.7
Grzeschik, S.8
Bieraugel, R.9
Green, J.10
-
243
-
-
84863229726
-
Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: A placebo-controlled double-blind parallel-group study
-
Harigai, M.; Tanaka, Y.; Maisawa, S. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: A placebo-controlled double-blind parallel-group study. J. Rheumatol. 2012, 39, 486-495.
-
(2012)
J. Rheumatol
, vol.39
, pp. 486-495
-
-
Harigai, M.1
Tanaka, Y.2
Maisawa, S.3
-
244
-
-
77954950402
-
Atacicept: Targeting B cells in multiple sclerosis
-
Hartung, H.P.; Kieseier, B.C. Atacicept: Targeting B cells in multiple sclerosis. Ther. Adv. Neurol. Disord. 2010, 3, 205-216.
-
(2010)
Ther. Adv. Neurol. Disord
, vol.3
, pp. 205-216
-
-
Hartung, H.P.1
Kieseier, B.C.2
-
245
-
-
33644755600
-
An APRIL to remember: Novel TNF ligands as therapeutic targets
-
Dillon, S.R.; Gross, J.A.; Ansell, S.M.; Novak, A.J. An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat. Rev. Drug Discov. 2006, 5, 235-246.
-
(2006)
Nat. Rev. Drug Discov
, vol.5
, pp. 235-246
-
-
Dillon, S.R.1
Gross, J.A.2
Ansell, S.M.3
Novak, A.J.4
-
246
-
-
3042569128
-
Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis
-
Thangarajh, M.; Gomes, A.; Masterman, T.; Hillert, J.; Hjelmstrom, P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J. Neuroimmunol. 2004, 152, 183-190.
-
(2004)
J. Neuroimmunol
, vol.152
, pp. 183-190
-
-
Thangarajh, M.1
Gomes, A.2
Masterman, T.3
Hillert, J.4
Hjelmstrom, P.5
-
247
-
-
33845710885
-
A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis
-
Thangarajh, M.; Masterman, T.; Hillert, J.; Moerk, S.; Jonsson, R. A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand. J. Immunol. 2007, 65, 92-98.
-
(2007)
Scand. J. Immunol
, vol.65
, pp. 92-98
-
-
Thangarajh, M.1
Masterman, T.2
Hillert, J.3
Moerk, S.4
Jonsson, R.5
-
248
-
-
24144460022
-
Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis
-
Thangarajh, M.; Masterman, T.; Rot, U.; Duvefelt, K.; Brynedal, B.; Karrenbauer, V.D.; Hillert, J. Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J. Neuroimmunol. 2005, 167, 210-214.
-
(2005)
J. Neuroimmunol
, vol.167
, pp. 210-214
-
-
Thangarajh, M.1
Masterman, T.2
Rot, U.3
Duvefelt, K.4
Brynedal, B.5
Karrenbauer, V.D.6
Hillert, J.7
-
249
-
-
0033428703
-
Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations
-
Mackay, F.; Woodcock, S.A.; Lawton, P.; Ambrose, C.; Baetscher, M.; Schneider, P.; Tschopp, J.; Browning, J.L. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 1999, 190, 1697-1710.
-
(1999)
J. Exp. Med
, vol.190
, pp. 1697-1710
-
-
Mackay, F.1
Woodcock, S.A.2
Lawton, P.3
Ambrose, C.4
Baetscher, M.5
Schneider, P.6
Tschopp, J.7
Browning, J.L.8
-
250
-
-
17944375043
-
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS
-
Gross, J.A.; Dillon, S.R.; Mudri, S.; Johnston, J.; Littau, A.; Roque, R.; Rixon, M.; Schou, O.; Foley, K.P.; Haugen, H. et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 2001, 15, 289-302.
-
(2001)
Immunity
, vol.15
, pp. 289-302
-
-
Gross, J.A.1
Dillon, S.R.2
Mudri, S.3
Johnston, J.4
Littau, A.5
Roque, R.6
Rixon, M.7
Schou, O.8
Foley, K.P.9
Haugen, H.10
-
251
-
-
49249090858
-
Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept
-
Carbonatto, M.; Yu, P.; Bertolino, M.; Vigna, E.; Steidler, S.; Fava, L.; Daghero, C.; Roattino, B.; Onidi, M.; Ardizzone, M. et al. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol. Sci. 2008, 105, 200-210.
-
(2008)
Toxicol. Sci
, vol.105
, pp. 200-210
-
-
Carbonatto, M.1
Yu, P.2
Bertolino, M.3
Vigna, E.4
Steidler, S.5
Fava, L.6
Daghero, C.7
Roattino, B.8
Onidi, M.9
Ardizzone, M.10
-
252
-
-
84856795563
-
Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial
-
Ginzler, E.M.; Wax, S.; Rajeswaran, A.; Copt, S.; Hillson, J.; Ramos, E.; Singer, N.G. Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial. Arthritis Res. Ther. 2012, 14, R33.
-
(2012)
Arthritis Res. Ther
, vol.14
-
-
Ginzler, E.M.1
Wax, S.2
Rajeswaran, A.3
Copt, S.4
Hillson, J.5
Ramos, E.6
Singer, N.G.7
-
253
-
-
79959856423
-
Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial
-
Van Vollenhoven, R.F.; Kinnman, N.; Vincent, E.; Wax, S.; Bathon, J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2011, 63, 1782-1792.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 1782-1792
-
-
van Vollenhoven, R.F.1
Kinnman, N.2
Vincent, E.3
Wax, S.4
Bathon, J.5
-
254
-
-
38149114077
-
Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study
-
Tak, P.P.; Thurlings, R.M.; Rossier, C.; Nestorov, I.; Dimic, A.; Mircetic, V.; Rischmueller, M.; Nasonov, E.; Shmidt, E.; Emery, P.; Munafo, A. Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008, 58, 61-72.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 61-72
-
-
Tak, P.P.1
Thurlings, R.M.2
Rossier, C.3
Nestorov, I.4
Dimic, A.5
Mircetic, V.6
Rischmueller, M.7
Nasonov, E.8
Shmidt, E.9
Emery, P.10
Munafo, A.11
-
255
-
-
77957126531
-
Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein
-
Harp, C.T.; Ireland, S.; Davis, L.S.; Remington, G.; Cassidy, B.; Cravens, P.D.; Stuve, O.; Lovett-Racke, A.E.; Eagar, T.N.; Greenberg, B.M., et al. Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur. J. Immunol. 2010, 40, 2942-2956.
-
(2010)
Eur. J. Immunol
, vol.40
, pp. 2942-2956
-
-
Harp, C.T.1
Ireland, S.2
Davis, L.S.3
Remington, G.4
Cassidy, B.5
Cravens, P.D.6
Stuve, O.7
Lovett-Racke, A.E.8
Eagar, T.N.9
Greenberg, B.M.10
|